WO2009121550A1 - Methods and assays for capture of nucleic acids - Google Patents

Methods and assays for capture of nucleic acids Download PDF

Info

Publication number
WO2009121550A1
WO2009121550A1 PCT/EP2009/002318 EP2009002318W WO2009121550A1 WO 2009121550 A1 WO2009121550 A1 WO 2009121550A1 EP 2009002318 W EP2009002318 W EP 2009002318W WO 2009121550 A1 WO2009121550 A1 WO 2009121550A1
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
target
probes
probe
sequence
Prior art date
Application number
PCT/EP2009/002318
Other languages
French (fr)
Inventor
Thomas Albert
Victor Lyamichev
Jigar Patel
Original Assignee
Roche Diagnostics Gmbh
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics Gmbh, F. Hoffmann-La Roche Ag filed Critical Roche Diagnostics Gmbh
Priority to JP2011502277A priority Critical patent/JP2011516050A/en
Priority to CN2009801199768A priority patent/CN102046811A/en
Priority to CA2725405A priority patent/CA2725405A1/en
Priority to EP09727453A priority patent/EP2262909A1/en
Publication of WO2009121550A1 publication Critical patent/WO2009121550A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6827Hybridisation assays for detection of mutation or polymorphism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6834Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips

Definitions

  • the present invention provides methods and systems for sequence specific nucleic acid target capture comprising enzymatic reactions.
  • the present invention comprises a plurality of oligonucleotide probes for capture and subsequent detection of target nucleic acid sequences, using flap endonucleases, ligases, and/or additional enzymes, proteins or compounds on substrates, for example microarray slides, and in solution formats.
  • nucleic acid microarray technology makes it possible to build an array of millions of nucleic acid sequences in a very small area, for example on a microscope slide (e.g., US 6,375,903 and US 5,143,854). Initially, such arrays were created by spotting pre-synthesized DNA sequences onto slides. However, the construction of maskless array synthesizers (MAS) as described in US 6,375,903 now allows for the in situ synthesis of oligonucleotide sequences directly on the slide itself.
  • MAS maskless array synthesizers
  • MAS-based oligonucleotide microarray synthesis technology allows for the parallel synthesis of over 4 million unique oligonucleotide features in a very small area of a standard microscope slide.
  • Nucleic acid microarray technology has been applied to many areas of research and diagnostics, such as gene expression and discovery, mutation detection, allelic and evolutionary sequence comparison, genome mapping, drug discovery, and more. Many applications require searching for genetic variants and mutations across the entire human genome; variants and mutations that, for example, may underlie human diseases. In the case of complex diseases, these searches generally result in a single nucleotide polymorphism (SNP) or set of SNPs associated with one or more diseases.
  • SNP single nucleotide polymorphism
  • Identifying such SNPs has proven to be an arduous, time consuming, and costly task wherein resequencing large regions of genomic DNA, usually greater than 100 kilobases (Kb) from affected individuals and/or tissue samples is frequently required to find a single base change or identify all sequence variants.
  • Kb kilobases
  • the present invention provides methods and systems for sequence specific nucleic acid target capture comprising enzymatic reactions.
  • the present invention comprises a plurality of oligonucleotide probes for capture and subsequent detection of target nucleic acid sequences, using flap endonucl eases, ligases, and/or additional enzymes, proteins or compounds on substrates, for example microarray slides, and in solution formats.
  • oligonucleotide probes are synthesized in situ, or synthesized and spotted onto a substrate, wherein said probes affixed to a substrate (e.g., microarray slide, bead, microsphere) and comprise a single stranded 5' end complementary to target sequence, and a 3' end comprising a hairpin structure and a terminal base complementary to a target nucleotide.
  • a substrate e.g., microarray slide, bead, microsphere
  • probes are synthesized comprising a single stranded 5' end further comprising a binding moiety, for example a biotin, attached to the 5' end of the probe, and a 3' end comprising a hairpin structure and terminal base complementary to a target sequence, and the probes are maintained in solution.
  • the hairpin structure as found in the probe comprises a sequence that is recognized and cleaved by a restriction endonuclease (RE).
  • RE restriction endonuclease
  • target nucleic acids include for example, genomic DNA or derivatives thereof, RNA, cDNA, microRNA (miRNA), noncoding RNA (ncRNA), promoter-associated small RNA (PASR), and the like are added to interact with the probes.
  • miRNA microRNA
  • ncRNA noncoding RNA
  • PASR promoter-associated small RNA
  • the nucleic acids are fragmented, for example by shearing, whereas in other embodiments nucleic acid targets are amplified, for example with PCR or by Klenow.
  • the target nucleic acids are labeled at the 3' end with a detectable moiety following fragmentation or amplification, for example a fluorescent, biotin, digoxygenin, etc. moiety.
  • a detectable moiety for example a fluorescent, biotin, digoxygenin, etc. moiety.
  • the present invention is not limited by the detection moiety and/or method used, and it is contemplated that a skilled artisan will understand the myriad options of detection moieties that can be attached to the 3' ends of nucleic acids for detection purposes.
  • the target nucleic acid sequences are at least 100 bp, at least 200 bp, at least 300 bp, at least 400 bp, at least 500 bp, at least 600 bp long.
  • the present invention is not limited to the size of the target nucleic acid sequences, and non-fragmented as well as fragmented and derived nucleic acid samples (e.g., PCR amplicons, Klenow random primed amplicons, etc.) are contemplated for use with methods and assays of the present invention.
  • the target nucleic acid sequence comprises a single nucleotide polymorphism or a copy number variation.
  • an interrogation nucleotide is positioned after the hairpin structure and at the 3 ' end of the probe. In some embodiments, the interrogation nucleotide is positioned, for example, immediately prior to the hairpin structure on the 5' side and the 3' end of the probe is designed to be complementary to a known target sequence. In some embodiments, the proximal nucleotide is 2, 3, 4, 5, 6, 7, 8, 9, or 10 bases upstream of the double stranded hairpin structure on the 5' side.
  • the interrogation nucleotide by positioning the interrogation nucleotide on the 5' side or arm of the probe sequence, a dual specificity with regards to both the cleavase and the ligase enzymes is realized as compared to cleavase specificity alone.
  • the cleavase specificity when the interrogation nucleotide is positioned on the 5' side as described, the cleavase specificity depends on the tripartite structures and a base specific substrate for ligation between the 3' end of the hairpin and the 5' end of the cleaved target.
  • labeled target nucleic acids are incubated with the probes, either on the substrate or in solution, under conditions suitable for hybridization to occur.
  • target sequences that are complementary to the terminal 3' nucleotide of the probe create a sequence specific structure that is recognized and cleaved by a flap endonuclease (FEN).
  • FEN flap endonuclease
  • a ligase enzyme in preferred embodiments, a thermostable ligase enzyme, is added to the reaction for ligating the 3' end of the probe to the 5' end of the cleaved target nucleic acid, thereby covalently linking the target nucleic acid to the probe.
  • the target sequence is not complementary to the 3 ' terminal nucleotide on the probe, then no cleavage structure is formed, no cleavage by the flap endonuclease occurs, and ligation cannot proceed.
  • the enzymatic reactions occur sequentially by adding the FEN to hybridized probe/target complexes, followed by separate addition of the ligase.
  • the FEN and ligase are added at the same time such that the reactions have the opportunity to occur more or less simultaneously.
  • RecJ exonuclease is added to the reaction in conjunction with a cleavase.
  • a ssDNA binding protein is additionally added to the reaction. The present invention is not limited to a particular mechanism.
  • RecJ and/or a ssDNA binding protein in conjunction with a FEN provides for enhanced activity of the cleavase in that the exonuclease activity of the RecJ in degrading long overhangs of hybridized target fragments provides for substrates more suitable for optimal cleavase activity compared to reactions when RecJ and/or a ssDNA binding are absent.
  • the non-specifically bound nucleic acid molecules are washed away from the covalently bound target molecules.
  • the labeled probes are maintained in solution, the labeled probes with the covalently bound target molecules are captured by a substrate, for example a bead, slide, plate, etc. coated with capture molecules.
  • a substrate for example a bead, slide, plate, etc. coated with capture molecules.
  • the substrates are washed to further purify the captured, target molecules away from the non-specifically bound nucleic acid molecules.
  • the substrate comprising the covalently bound targets is scanned using a fluorescent scanner, for example, to detect the fluorescent moiety found on the target sequence, and data containing sequence information is communicated to a user, for example via a computer or other visualization means.
  • the bound target nucleic acids are released from the substrate for downstream applications such as sequencing.
  • the hairpin structure of the probe comprises one or more restriction endonuclease sites or uracils.
  • the present invention is not limited to any particular cleavable sequence, and a skilled artisan will recognize the myriad of options that are amenable to methods and assays of the present invention.
  • the target sequence is released from the probe by digesting the probe/target complex with a RE, or uracil-DNA-glycosylase followed by endonuclease VIII digestion, wherein the sequence recognized by the RE is found in the hairpin structure of the probe or uracils were synthesized into the probe hairpin.
  • the target sequences are eluted from the probe using methods known to those skilled in the art, for example by incubating the target sequence/probe complexes in water or a low solute solution. The eluted target molecules are applied to downstream applications, for example sequencing reactions.
  • Methods and assays of the present invention as described herein find utility, for example, in detecting single nucleotide polymorphisms, genomic copy number variations, and the like. Genomic anomalies can be studied for their association with diseases and disorders, thereby providing insight into the causes of diseases and disorders for research and diagnostic purposes, as well as providing potential targets for use in drug discovery in identifying therapeutic treatments for such diseases and disorders.
  • the present invention provides a method for capturing target nucleic acid sequences comprising providing a nucleic acid sample wherein said sample comprises a detection moiety, preferably a fluorescent moiety such as Cy-3, and may or may not comprise a target sequence, at least one flap endonuclease, at least one ligase, preferably a thermostable ligase, and a plurality of oligonucleotide probes, wherein said probes comprise target sequences and a hairpin structure, applying said nucleic acid sample to said oligonucleotide probes under conditions for hybridization to occur, applying said flap and ligase enzymes to said hybridized nucleic acid/probe complex under conditions allowing for enzymatic reactions to occur thereby capturing said target nucleic acid sequences.
  • a detection moiety preferably a fluorescent moiety such as Cy-3
  • ligase preferably a thermostable ligase
  • a plurality of oligonucleotide probes wherein
  • the nucleic acid sample is a genomic DNA sample or a derivative thereof, wherein said sample is from a mammal, preferably a human.
  • at least one of said target sequences includes a single nucleotide polymorphism, while in other embodiments the target sequence is a genomic copy number variant.
  • the hairpin structure comprises SEQ ID NO: 1.
  • the captured target nucleic acids are further detected, for example using a fluorescent scanner.
  • the probes are affixed to a substrate, for example a microarray slide, while in other embodiments the probes are maintained in solution. In some embodiments, the probes are associated with gel pads.
  • the present invention provides a method for capturing target nucleic acid sequences comprising providing a nucleic acid sample wherein said sample comprises a detection moiety, preferably a fluorescent moiety such as, for example, Cy-3, and may or may not comprise a target sequence, at least one flap endonuclease, at least one ligase, preferably a thermostable ligase, and a plurality of oligonucleotide probes, wherein said probes comprise target sequences and a hairpin structure wherein said hairpin structure comprises cleavable sequences, providing conditions for hybridization to occur between the probes and the target nucleic acids, applying said flap and ligase enzymes to said hybridized nucleic acid/probe complex under conditions allowing for enzymatic reactions to occur thereby capturing said target nucleic acid sequences.
  • a detection moiety preferably a fluorescent moiety such as, for example, Cy-3
  • ligase preferably a thermostable ligase
  • RecJ exonuclease and a ssDNA binding protein are included in the reaction in conjunction with a flap endonuclease.
  • the cleavable sequences comprise a restriction endonuclease site, recognized and cleavable by a restriction endonuclease.
  • the target nucleic acids are released from the probes by restriction endonuclease digest followed by sequencing for detection of the target sequences.
  • the present invention provides a composition for sequence specific nucleic acid capture on a substrate or in solution comprising a flap endonuclease, a ligase, and oligonucleotide probes wherein said probes comprise a hairpin structure and complementary target nucleic acid sequences.
  • the oligonucleotide probes are affixed to a substrate, for example a microarray slide or a bead.
  • the present invention includes a kit, wherein said kit is used for capturing nucleic acid target sequences comprising at least one flap endonuclease, at least one thermostable ligase, a plurality of oligonucleotide probes affixed to a substrate or in a purified state, and at least one buffer.
  • said kit is used for capturing nucleic acid target sequences comprising at least one flap endonuclease, at least one thermostable ligase, a plurality of oligonucleotide probes affixed to a substrate or in a purified state, and at least one buffer.
  • RecJ exonuclease and a ssDNA binding protein are further included in a kit.
  • the oligonucleotide probes consists essentially of a single stranded 5' end complementary to a target sequence, and a 3' end consisting essentially of a hairpin structure and a terminal base complementary to a target nucleotide.
  • the interrogation nucleotide is positioned on the 5 'side of the probe.
  • the present invention includes a kit, wherein said kit is used for capturing nucleic acid target sequences and consists essentially of at least one flap endonuclease, at least one thermostable ligase, a plurality of oligonucleotide probes affixed to a substrate or in a purified state, RecJ exonuclease, a ssDNA binding protein and at least one buffer.
  • sample includes a nucleic acid specimen obtained from any source.
  • Biological nucleic acid samples may be obtained from animals (including humans) and encompass nucleic acids isolated from fluids, solids, tissues, etc.
  • Biological nucleic acid sample may also come from non-human animals, including, but are not limited to, vertebrates such as rodents, non-human primates, ovines, bovines, ruminants, lagomorphs, porcines, caprines, equines, canines, felines, aves, etc.
  • Biological nucleic acids may also be obtained from prokaryotes, like bacteria and other non-animal eukaryotes such as plants. It is contemplated that the present invention is not limited by the source of nucleic acids sample, and any nucleic acid from any biological Kingdom finds utility in methods as described herein.
  • nucleic acid molecule refers to any nucleic acid containing molecule from any sample source, including but not limited to, DNA or RNA.
  • the term encompasses sequences that include any of the known base analogs of DNA and RNA including, but not limited to, 4-acetylcytosine, 8-hydroxy-N6- methyladenosine, aziridinylcytosine, pseudoisocytosine, 5-(carboxyhydroxyl- methyl) uracil, 5-fluorouracil, 5-bromouracil, 5- carboxymethylaminomethyl-2-thiouracil, 5-carboxymethylaminomethyluracil, dihydrouracil, inosine, N6-isopentenyladenine, 1-methyladenine, 1-methylpseudo- uracil, 1 -methylguanine, 1 -methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3 -methyl cytos
  • oligonucleotide refers to a molecule comprised of two or more deoxyribonucleotides or ribonucleotides, preferably more than three, and usually more than ten. The exact size will depend on many factors, which in turn depends on the ultimate function or use of the oligonucleotide.
  • the oligonucleotide may be generated in any manner, including chemical synthesis, DNA replication, reverse transcription, or a combination thereof.
  • the term oligonucleotide may also be used interchangeably with the term “polynucleotide.”
  • the terms “complementary” or “complementarity” are used in reference to polynucleotides related by the base-pairing rules.
  • the sequence “5'-A-G-T-3', M is complementary to the sequence "3'-T-C-A-5 ⁇ "
  • Complementarity may be “partial,” in which only some of the nucleic acids' bases are matched according to the base pairing rules. Or, there may be “complete” or “total” complementarity between the nucleic acids. The degree of complementarity between nucleic acid strands has significant effects on, for example, the efficiency and strength of hybridization between nucleic acid strands, amplification specificity, etc.
  • hybridization is used in reference to the pairing of complementary nucleic acids. Hybridization and the strength of hybridization (i.e., the strength of the association between the nucleic acids) is impacted by such factors as the degree of complementary between the nucleic acids, stringency of the conditions involved, the Tm of the formed hybrid, and the G:C ratio within the nucleic acids. While the invention is not limited to a particular set of hybridization conditions, stringent hybridization conditions are preferably employed. Stringent hybridization conditions are sequence-dependent and will differ with varying environmental parameters (e.g., salt concentrations, and presence of organics).
  • stringent conditions are selected to be about 5 °C to 20 °C lower than the thermal melting point (Tm) for the specific nucleic acid sequence at a defined ionic strength and pH.
  • Tm thermal melting point
  • stringent conditions are about 5 °C to 10 0 C lower than the thermal melting point for a specific nucleic acid bound to a complementary nucleic acid.
  • the Tm is the temperature (under defined ionic strength and pH) at which 50 % of a nucleic acid hybridizes to a perfectly matched probe.
  • stringency is used in reference to the conditions of temperature, ionic strength, and the presence of other compounds such as organic solvents, under which nucleic acid hybridizations are conducted.
  • low stringency conditions a nucleic acid sequence of interest will hybridize to its exact complement, sequences with single base mismatches, closely related sequences (e.g., sequences with 90 % or greater homology), and sequences having only partial homology (e.g., sequences with 50-90 % homology).
  • intermediate stringency conditions a nucleic acid sequence of interest will hybridize only to its exact complement, sequences with single base mismatches, and closely relation sequences (e.g., 90 % or greater homology).
  • a nucleic acid sequence of interest will hybridize only to its exact complement, and (depending on conditions such a temperature) sequences with single base mismatches. In other words, under conditions of high stringency the temperature can be raised so as to exclude hybridization to sequences with single base mismatches.
  • stringent conditions or “high stringency conditions,” comprise hybridization in 50 % formamide, 5x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1 % sodium pyrophosphate, 5x Denhardt's solution, sonicated salmon sperm DNA (50 mg/ml), 0.1 % SDS, and 10 % dextran sulfate at 42 °C, with washes at 42 °C in 0.2x SSC (sodium chloride/sodium citrate) and 50 % formamide at 55 0 C, followed by a wash with O.lx SSC containing EDTA at 55 °C.
  • buffers containing 35 % formamide, 5x SSC, and 0.1 % (w/v) sodium dodecyl sulfate are suitable for hybridizing at 45 °C for 16-72 hours.
  • formamide concentration may be suitably adjusted between a range of 0-45 % depending on the probe length and the level of stringency desired.
  • probe optimization is obtained for longer probes (for example, greater than 50 mers) by increasing the hybridization temperature or the formamide concentration to compensate for a change in the probe length. Additional examples of hybridization conditions are provided in many reference manuals, for example in "Molecular Cloning: A Laboratory Manual", as referenced and incorporated herein.
  • stringent wash conditions are ordinarily determined empirically for hybridization of target sequences to a corresponding probe array. For example, the arrays are first hybridized and then washed with wash buffers containing successively lower concentrations of salts, or higher concentrations of detergents, or at increasing temperatures until the signal-to-noise ratio for specific to nonspecific hybridization is high enough to facilitate detection of specific hybridization.
  • stringent temperature conditions will usually include temperatures in excess of about 30 °C, more usually in excess of about 37 °C, and occasionally in excess of about 45 °C.
  • Stringent salt conditions will ordinarily be less than about 1000 mM, usually less than about 500 mM, more usually less than about 150 mM.
  • hybridization and wash solutions are utilized as found commercially available through Roche- NimbleGen (e.g., NimbleChipTM CGH Arrays, NimbleGen Hybridization Kits, etc.).
  • the term "primer” refers to an oligonucleotide, whether occurring naturally as in a purified restriction digest or produced synthetically, that is capable of acting as a point of initiation of synthesis when placed under conditions in which synthesis of a primer extension product that is complementary to a nucleic acid strand is induced, (i.e., in the presence of nucleotides and an inducing agent such as DNA polymerase and at a suitable temperature and pH).
  • the primer is preferably single stranded for maximum efficiency in amplification, but may alternatively be double stranded. If double stranded, the primer is first treated to separate its strands before being used to prepare extension products.
  • the primer is an oligodeoxyribonucleotide.
  • the primer must be sufficiently long to prime the synthesis of extension products in the presence of the inducing agent. The exact lengths of the primers will depend on many factors, including temperature, source of primer and the use of the method.
  • probe refers to an oligonucleotide (i.e., a sequence of nucleotides), whether occurring naturally as in a purified restriction digest or produced synthetically, recombinantly or by PCR amplification, that is capable of hybridizing to at least a portion of another oligonucleotide of interest.
  • a probe may be single-stranded or double-stranded, however in the present invention the probes are intended to be single stranded. Probes are useful in the detection, identification and isolation of particular gene sequences. Probes, in embodiments of the present invention, comprise a 5' single stranded end and a 3' end comprising a hairpin structure. A restriction endonuclease site may or may not be present in the hairpin structure.
  • the term "derivative thereof of "portion” or “fragment” when in reference to a nucleotide sequence refers to fragments of that sequence.
  • the fragments may range in size from four nucleotides to the entire nucleotide sequence minus one nucleotide (10 nucleotides, 20, 30, 40, 50, 100, 200, etc.). Fragments can be obtained through, for example, sonication, PCR amplification, Klenow amplification, or any other means known in the art for reducing a nucleotide sequence to smaller sequences thereof.
  • fragments, derivatives of nucleic acid sequences are preferably at least 200 bp, at least 300 bp, at least 400 bp, at least 500 bp, at least 600 bp.
  • the present invention is not limited to the size of the target nucleic acid sequences.
  • purified refers to the removal of components (e.g., contaminants) and/or contaminants from a sample.
  • purified refers to molecules, either nucleic or amino acid sequences that are removed from their natural environment, isolated or separated.
  • An "isolated nucleic acid sequence or sample” is therefore a purified nucleic acid sequence or sample.
  • substantially purified molecules are at least 60 % free, preferably at least 75 % free, and more preferably at least 90 % free from other components with which they are naturally associated.
  • purified relates to the separation of unbound sample nucleic acid molecules and reaction components (e.g., enzymes, etc.) away from probe/target complexes, typically by washing with wash buffers of one or more stringencies, thereby "purifying" the probe/target nucleic acid complexes from other reaction components.
  • reaction components e.g., enzymes, etc.
  • the term "interrogation nucleotide” refers to the nucleotide in the probe that interacts with (e.g, matching base pair formation or a mismatch) the target sequence to determine a specific mutation such as a single nucleotide polymorphism or for sequence-specific capture of target nucleotides from a sample using a plurality of oligonucleotide probes.
  • the interrogation nucleotide is positioned as a terminal base at the 3 'end of the probe.
  • the interrogation nucleotide is positioned on the 5 '-side or arm of the probe (i.e., the single stranded region of the probe), proximal to the hairpin stem structure. In some embodiments, interrogation nucleotide is positioned immediately next to and upstream of the hairpin stem structure. In some embodiments, the proximal nucleotide is 2, 3, 4, 5, 6, 7, 8, 9, or 10 bases upstream of the double stranded hairpin structure on the 5' side.
  • the interrogation nucleotide may also be referred as "allele specific nucleotide". In some embodiments, the interrogation nucleotide, if a corresponding complementary nucleotide is present in the target, creates an overlapping tripartite structure with the target molecule that is recognized by a cleavase.
  • Figure 1 shows an exemplary embodiment for the use of flap endonucleases and ligases to cleave and ligate target molecules to probes affixed to a microarray solid support;
  • Figure 2 demonstrates an exemplary embodiment for the use of flap endonucleases and ligases to cleave and ligate target molecules to labeled probes in solution; A) sequence specific cleavage followed by ligation of target molecules (SEQ ID NO: 33) to a biotinylated probe (SEQ ID NO: 32) when an invasive complex is formed, and B) capture of labeled probes with covalently attached target molecules to beads coated with streptavidin.
  • Figure 3 shows an exemplary hairpin sequence of an oligonucleotide probe
  • target sequences are captured by probes with hairpins, FEN cleaved, and ligated to the probe, whereas control sequences are not.
  • Figure 5 shows experimental data demonstrating the efficiency of methods of the present invention in capturing target sequences (correct vs. incorrect base call), and the fold difference in capturing the correct versus the incorrect target sequence.
  • Figure 6 demonstrates the three different E-coli amplifications and the restriction digest maps for created fragmented experimental
  • Figure 7 exemplifies the use of the present invention is identifying genomic mutations.
  • Figure 8 demonstrates the effect of 5' flap length on the activity of different cleavase molecules with regards to the ability to correctly perform base calling as indicated by low discrimination scores ( ⁇ 0.5 D score).
  • Figure 9 exemplifies the effect of RecJ in enhancing cleavase activity; A) demonstrates cleavase reactions without RecJ and B) demonstrates the enhanced activity of a cleavase in the presence of Red.
  • Figure 10 illustrates a comparison of hairpin configuration for single vs. dual enzymatic specificity in cleavase and ligase reactions.
  • A, C) Hairpin configurations have, for example, oligomer probes (SEQ ID NO: 1
  • Hairpin configurations have, for example, oligomer probes (SEQ ID NOS: 16-19, 38-41) synthesized from 5'-3' with a hairpin of stem-length (6 bp - 12 bp). These generate base specific substrates for ligation between the 3' end of the hairpin and the 5' end of the cleaved targets (SEQ ID NOS: 15, 42).
  • OL refers to overlap at an interrogation site. Therefore, OLl refers to an overlap of 1 nucleotide and OLO refers to zero or no overlap at the interrogation site.
  • Figure 11 shows the evaluation of specificity of base calling using various hairpin configurations across an 83 bp PCR fragment. Discrimination scores were calculated for every base across the 83 bp fragment and plotted against two classes of hairpin configurations; 1) Dual (OLO) and 2) Single (OLl) enzyme specificity. Within each class, several stem and loop sequences were compared. The control probeset with no hairpins (No HP) had the lowest discrimination, whereas the dual enzymatic hairpin configuration had the highest.
  • Figure 12 shows the evaluation of specificity of base calling using various hairpin configurations across an 83 bp PCR fragment.
  • Discrimination scores were calculated for every base across the 83 bp fragment and plotted against two classes of hairpin configurations; 1) Dual (OLO) (SEQ ID NOS: 20-25) and 2) Single (OLl) (SEQ ID NOS: 26-31) enzyme specificity. Within each class, several stem and loop sequences were compared.
  • the present invention provides methods and assays for the use of flap endonucl eases and ligases in methods and assays for targeted capture of nucleic acids on solid substrates and in solution. Certain illustrative embodiments of the invention are described below. The present invention is not limited to these embodiments.
  • Flap endonucleases also known as cleavases, are structure specific enzymes that are capable of cleaving nucleic acids in a sequence specific manner.
  • the enzymes have been used as components in the development of the Invader® genotyping and nucleic acid detection technology from Third Wave Technologies, for example as found in US Patents and Published Patent Applications 5,843,669, 5,888,780, 6,090,606, 6,562,611, 7,122,364, 2007/0003942, 2007/0292856, 2006/0292580, 2006/0183207, 2006/0177835, 2006/0154269 and 2006/0040294, all of which are incorporated herein by reference in their entireties.
  • flap endonuclease compositions and methods are found in US Patents and Published Patent Applications 6,255,081, 6,251,649, 6,979,725, 5,874,283, 2007/0292934, 2007/0292864, 2007/0231815, and 2007/0105138, all of which are incorporated herein by reference in their entireties.
  • the endonuclease activity of FENs includes recognition of a DNA duplex which has a 5' overhang (flap) on one of the strands, called the invasive complex (as exemplified in Figures 1 and 2).
  • the FEN catalyses hydrolytic cleavage of the phosphodiester bond at the junction of the single and double stranded DNA (Harrington, JJ., and Lieber, M.R., EMBO J 13(5) (1994) 1235-46; Harrington, J.J., and Lieber, M.R., J Biol Chem 270(9) (1995) 4503-8; incorporated herein be reference in their entireties).
  • the ability of FENs to recognize and cleave specific secondary structures allows these enzymes to be used to detect internal sequence differences in nucleic acids without prior knowledge of the specific sequence of the nucleic acid.
  • the specific structure recognized by FENs is created and FEN cleavage occurs.
  • the sequence as found in the probe is not complementary to the target sequence, no structure is realized and FEN cleavage does not occur. As such, sequence specific recognition of target nucleic acids is achieved.
  • Ligases in particular thermostable ligases, are further contemplated for use with methods and assays of the present invention. Ligation of the probe 3' end to the 5' end of the target molecule is performed following FEN cleavage of the target molecule, if the FEN recognized structure is present.
  • ligases catalyse the formation of covalent phosphodiester bonds between juxtaposed 3' hydroxyl and 5' phosphate termini in duplex DNA or RNA (exemplified in Figures 1 and T).
  • thermostable ligases are contemplated.
  • Non-thermostable ligases such as T4 DNA ligase demonstrate optimal enzymatic activity at room temperature.
  • Thermostable ligases for example those found in the bacteria Thermus aquaticus and Pyrococcus furiosus, demonstrate optimal enzymatic activity at much higher temperatures, for example greater than 45 °C, allowing more flexibility in temperature conditions when applied to methods and assays of the present invention as described herein.
  • thermostable ligases are found in, for example, US Patents and Published Patent Applications 6,949,370, 6,576,453, 6,280,998, 6,444,429, 5,700,672, 2007/0037190, 2005/0266487 and European Patent Publication WO 07/035439, all of which are incorporated herein by reference in their entireties.
  • ligation via a ligase enzyme covalently links the target sequence to the probe, wherein said probe is either affixed to a solid support, for example a microarray slide, or kept in solution.
  • a solid support for example a microarray slide, or kept in solution.
  • RecJ Rec J exonuclease
  • SSBP ssDNA binding protein
  • Rec J degrades both phosphorylated and unphosphorylated DNA ends with equal affinity, however requires that the single stranded end be at least 7 nucleotides long. Rec J is a processive exonuclease and degrades approximately 1000 nucleotides after it binds to the single stranded end, typically stopping when it comes to the double stranded DNA junction. However, RecJ nuclease activity is not precise, and it may stop degradation activity a few nucleotides short of the junction or a few base pairs after the function.
  • oligonucleotide probes are attached to a solid support, such as a microarray slide, at their 5' ends or 5 'sides or 5' arms, wherein said probes comprise a central portion that is single stranded and complementary to a target sequence, and a 3 ' terminal region that comprises a hairpin structure comprising a loop of single nucleotides bounded by double stranded region of complementary nucleic acids, ending in a 3' terminal base specific to a target sequence of interest (e.g., an interrogation nucleotide for determining a genomic mutation such as single nucleotide polymorphism).
  • a target sequence of interest e.g., an interrogation nucleotide for determining a genomic mutation such as single nucleotide polymorphism.
  • the base that is specific to the target sequence e.g., for determining a mutation or a polymorphism is placed immediately proximate to the hairpin loop structure on the 5 '-side of the probe.
  • the double stranded hairpin region is at least 3 base pairs, at least 5 base pairs, at least 6 base pairs, at least 8 base pairs, at least 10 base pairs, at least 16 base pairs.
  • the nucleic acid probes are incubated with a complex target population of nucleic acid strands (e.g., DNA, cDNA, gDNA, RNA, mRNA, tRNA, etc.), for example human genome DNA (gDNA) (e.g., whole or fragmented), under conditions that favor hybridization of complementary DNA strands such that nucleic acid sequences complementary to the single stranded portion of the 5' end of the nucleic acid probe and the probe 3' terminal base specifically hybridize to the probe.
  • the target nucleic acids are labeled on the 3' end with, for example, a detectable moiety (e.g., fluorophore, chromophore, radioisotope, etc.).
  • the present invention provides oligonucleotide probes attached to a solid support, such as a microarray slide, at their 5' ends, wherein said probes comprise a central portion that is single stranded and partially complementary to a target sequence, and a 3' terminal region that comprises a hairpin structure comprising a loop of single nucleotides bounded by a double stranded region of complementary nucleic acids, ending in a 3' terminal base complementary to a target sequence, wherein a nucleotide proximal to the 5' end of the double stranded region of complementary nucleic acids that comprise a hairpin structure includes a sequence complementary to a target sequence of interest (e.g., an interrogation nucleotide for determining genomic mutations such as single nucleotide polymorphisms).
  • a target sequence of interest e.g., an interrogation nucleotide for determining genomic mutations such as single nucleotide polymorphisms.
  • the proximal nucleotide is immediately proximate to the double stranded hairpin structure.
  • the proximal nucleotide is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 bases upstream of the double stranded hairpin structure on the 5' side.
  • the double stranded hairpin region is at least 3 base pairs, at least 10 base pairs, at least 16 base pairs.
  • the nucleic acid probes are incubated with a complex target population of nucleic acid strands (e.g., DNA, cDNA, gDNA, RNA, mRNA, tRNA, etc.), for example human genome DNA (gDNA) (e.g., whole or fragmented), under conditions that favor hybridization of complementary DNA strands such that nucleic acid sequences complementary to the single stranded portion of the 5' end of the nucleic acid probe and the probe 3' terminal base specifically hybridize to the probe.
  • the target nucleic acids are labeled on the 3' end with, for example, a detectable moiety (e.g., fluorophore, chromophore, radioisotope, etc.).
  • the present invention provides oligonucleotide probes attached to a solid support, such as a microarray slide, at their 5' ends, wherein said probes comprise a central portion that is single stranded and complementary to a target sequence, and a 3' terminal region that comprises a hairpin structure comprising a loop of single nucleotides bounded by a double stranded region of complementary nucleic acids, ending in a 3' terminal base complementary to a target sequence.
  • the double stranded hairpin region is at least 3 base pairs, at least 10 base pairs, at least 16 base pairs.
  • the nucleic acid probes are incubated with a complex target population of nucleic acid strands (e.g., DNA, cDNA, gDNA, RNA, mRNA, tRNA, etc.), for example human genome DNA (gDNA) (e.g., whole or fragmented), under conditions that favor hybridization of complementary DNA strands such that nucleic acid sequences complementary to the single stranded portion of the 5' end of the nucleic acid probe and the probe 3 ' terminal base specifically hybridize to the probe.
  • the target nucleic acids are labeled on the 3' end with, for example, a detectable moiety (e.g., fluorophore, chromophore, radioisotope, etc.).
  • oligonucleotide probes comprising a central portion that is single stranded and complementary to a target sequence, and a 3' terminal region that comprises a hairpin structure comprising a loop of single nucleotides bounded by a double stranded region of complementary nucleic acids, ending in a 3' terminal base complementary to a target sequence find utility in hybridization assays for determining genetic anomalies such as deletions, translocations, and the like.
  • oligonucleotide probes are synthesized and affixed to a substrate, for example a microarray slide or chip, as described in DNA Microarrays: A Molecular Cloning Manual, 2003, Eds. Bowtell and Sambrook, Cold Spring Harbor Laboratory Press, incorporated herein by reference in its entirety.
  • capture oligonucleotide probes are synthesized directly on a substrate, such as a microarray slide, using maskless array synthesizers (MAS), for example as described in US Patents and Patent Publications 7,157,229, 7,083,975, 6,444,175, 6,375,903, 6,315,958, 6,295,153, 5,143,854, 2007/0037274, 2007/0140906, 2004/0126757, 2004/0110212, 2004/0110211, 2003/0143550, 2003/0003032, and 2002/0041420, all of which are incorporated herein by reference in their entireties.
  • MAS maskless array synthesizers
  • oligonucleotide probe sequences are constructed in situ directly on the microarray slide under software control, such that individually customized arrays based on the particular needs of an investigator are created.
  • arrays comprise hundreds, thousands, and millions of probes.
  • Oligonucleotide probes are typically synthesized from 3' to 5', whether synthesized in situ (e.g., MAS synthesis) on a substrate (e.g., microarray slide) or synthesized and then spotted onto a substrate.
  • a substrate e.g., microarray slide
  • nucleic acid enzymes e.g., restriction endonucleases, polymerases, terminal transferase, ligases, kinases, phosphatases, etc.
  • reverse chemistries e.g., from 5' to 3'.
  • method and assay embodiments of the present invention comprise in situ synthesis of oligonucleotide probes synthesized preferentially from 5' to 3' using MAS instruments as described in, for example, Albert, T.J., et al., Nucl Acids Res 31(7) (2003) e35; incorporated herein by reference in its entirety).
  • the present invention provides methods and assays for detecting differences in nucleic acid sequences, for example single nucleotide polymorphisms, genomic copy number variants, methylation status, etc.
  • target nucleic acids are hybridized with probes, wherein said probes are affixed (e.g., via in situ synthesis or otherwise) to a substrate or found in solution.
  • the probes are at least 15 nucleotides (nts) long, at least 20 nts, at least 25 nts, at least 30 nts, at least 35 nts, at least 40 nts, at least 45 nts, at least 50 nts, at least 55 nts, at least 60 nucleotides long.
  • probes of the present invention are synthesized in situ on a substrate, for example a microarray slide, microarray chip, bead, plate, etc.
  • the probes are synthesized in situ using MAS instrumentation wherein the 5' terminus of the probe is affixed to the substrate.
  • the probes are synthesized in solution and maintained in solution.
  • Probes of the present invention comprise a single stranded 5' end complementary to a target sequence, a 3' end that comprises a hairpin structure comprising a series of complementary bases that create a double stranded region and sequences that are not complementary that create a single stranded region amid the double stranded region (e.g., hairpin structure), and a 3' terminal base complementary to a specific target sequence.
  • the hairpin structure is at least 5 bases, 10 bases, at least 12 bases, at least 14 bases, at least 16 bases, at least 18 bases long.
  • the hairpin structure is preferably 16 bases.
  • the hairpin structure comprises SEQ ID NO: 1, as exemplified in Figure 3.
  • the present invention is not limited by the sequence of the hairpin structure, and further examples of hairpin structures and their design are found in Varani, G., Ann Rev Biophys Biomol Struct 24 (1995) 379-404 and Antao, V.P., et al., Nucl Acids Res 19(21) (1991) 5901-5, both of which are incorporated herein by reference in their entireties.
  • the nucleotide base on the probe that is complementary to the 3' terminal base of the probe hairpin determines assay specificity, and is sometimes referred to as the "allele specific base”.
  • the nucleotide base on the 5'- side or arm of the probe proximal to the hairpin structure also determines assay specificity.
  • the hairpin and target molecules form a specific structure, termed the "invasive complex" that is recognized by FEN enzymes.
  • FEN cleaves the target strand on the 3' side of the base thereby releasing the non-hybridized, or flap, 5' end of the target strand. If the base is not complementary to the allele specific base, then the invasive complex does not form, and the target molecule is not cleaved by the FEN.
  • the probe/target complex is incubated with a cocktail comprising one or more of a flap endonuclease (FEN), ligase, Rec J, a ssDNA binding protein, and appropriate buffers and cofactors (ATP or NAD+) necessary for enzymatic reactions to occur.
  • FEN flap endonuclease
  • ligase ligase
  • Rec J Rec J
  • ssDNA binding protein a ssDNA binding protein
  • ATP or NAD+ buffers and cofactors
  • Ligase repairs the gap, covalently attaching the target molecule to the probe. If the invasive complex does not form, then the FEN does not cleave and the target molecule is not ligated to the probe. Unbound molecules are subsequently separated from the bound targets by washing. Since the target molecules are covalently attached to the probes on the substrate, washing can be performed with much higher stringency that those afforded to non-covalently bound hybridization methods, thereby increasing the removal of non-specifically bound, non-target molecules and greatly improving capture specificity and signal-to-noise ratios.
  • target molecules that bind to the probe are identified by a detectable means (e.g. colorimetry, radiometry, fluorometry, gel electrophoresis, etc.) using data analysis instruments and software as described herein and as known to a skilled artisan.
  • a detectable means e.g. colorimetry, radiometry, fluorometry, gel electrophoresis, etc.
  • the arrays are capable of being washed with high stringency for removal of unbound, non-target molecules thereby allowing for increased reduction of background signal and increasing an assay's signal-to noise ratio.
  • Applications of the present invention include, but are not limited to, comparative genomic hybridization (CGH), single nucleotide polymorphism genotyping, gene transcription profiling, genome methylation analysis, chromatin immunoprecipitation mapping, and the like.
  • the present invention provides assays and methods for target capture of DNA for, for example, high throughput sequencing applications and other downstream applications.
  • nucleic acid probes are in solution and bound at their 5' ends to a capturable moiety, for example a biotin moiety ( Figure 2).
  • the nucleic acid probes further comprise a 5' region that is single stranded and complementary to a target sequence and a 3' terminal region that comprises a hairpin structure comprising a loop of single nucleotides bounded by a double stranded region of complementary nucleic acids as previously described.
  • the hairpin structure is at least 5 bases, 10 bases, at least 12 bases, at least 14 bases, at least 16 bases, at least 18 bases long.
  • the probes are at least 15 nucleotides (nts) long, at least 20 nts, at least 25 nts, at least 30 nts, at least 35 nts, at least 40 nts, at least 45 nts, at least 50 nts, at least 55 nts, at least 60 nucleotides long. It is contemplated that the probe is preferably less than 100 bases.
  • the hairpin sequences comprise cleavable sequences for releasing the bound target sequences from the probe following ligation.
  • the hairpin sequences comprise a restriction endonuclease (RE) site or one or more uracils.
  • RE restriction endonuclease
  • the nucleic acid probes are incubated with a complex target population of nucleic acid strands (e.g., DNA, cDNA, gDNA, RNA, mRNA, tRNA, etc.), for example fragmented human genome DNA (gDNA), under conditions that favor hybridization of complementary DNA strands such that fragments of the genome complementary to the single stranded portion of the 5' end of the nucleic acid probe specifically hybridize to the probe.
  • the target nucleic acids are labeled on the 3 ' end with, for example, a detectable moiety (e.g., fluorophore, chromophore, radioisotope, etc.).
  • the hairpin and target molecules hybridize and form a specific structure that is recognized by FEN enzymes.
  • FEN cleaves the target strand on the 3' side of the base thereby releasing the non-hybridized, or flap, 5' end of the target strand. If the base is not complementary to the allele specific base, then the invasive complex does not form, and the target molecule is not cleaved by the FEN. It is contemplated that the incorporation of RecJ with or without a ssDNA binding protein in conjunction with a FEN will increase the efficiency of the cleavase enzyme.
  • the probe complex is incubated with a cocktail comprising one or more of a FEN enzyme, ligase enzyme, RecJ, a ssDNA binding protein, appropriate buffers and cofactors (ATP or NAD+) necessary for the required enzymatic reactions to occur.
  • the FEN cleaves target molecules that form the invasive complex, resulting in a gap between the nucleic acid probe hairpin and the target nucleic acid molecule.
  • the ligase repairs the gap by covalently attaching the target molecule to the probe.
  • the FEN does not cleave and the target molecule is not ligated to the probe, hi some embodiments, as exemplified in Figure 2B, the target molecules that are covalently attached to a labeled probe in solution, in this instance a biotin labeled probe, are captured (e.g., bound) by streptavidin (SA) coated beads, wherein streptavidin binds the biotin of the labeled probe as known to those skilled in the art. Following streptavidin binding, the beads are removed from solution and washed thereby removing unbound, untargeted molecules from the bound target molecules on the captured beads and purifying the target molecule/probe complexes away from unwanted reaction components.
  • SA streptavidin
  • target molecules are covalently attached to the SA bound biotin labeled probe, washing can be performed with much higher stringency that those afforded to non-covalently bound hybridization methods, thereby increasing the removal of non-specifically bound, non-target molecules and greatly improving capture specificity and signal-to-noise ratios.
  • the target molecules are released from the SA bound probe by exposing the beads comprising the target molecules to a restriction endonuclease, for example when the recognition site of the RE is incorporated into the hairpin sequence of the probe during synthesis.
  • a restriction endonuclease for example when the recognition site of the RE is incorporated into the hairpin sequence of the probe during synthesis.
  • the target molecules are released from the SA bound probes by incubation with uracil-DNA-glycosylase (UDG) followed by Endonuclease VIII digestion at the damaged site.
  • UDG uracil-DNA-glycosylase
  • the targeted molecules are applied to downstream applications, such as sequencing using, for example, a high-throughput sequencer.
  • Methods and assays of the present invention further provide an investigator the ability to precisely define the end point and directionality of each captured target nucleic acid molecule and, as a consequence, each sequencing read. It is contemplated that release of the target sequence using enzymatic means as described herein is amenable to release of target sequences from probes wherein said probes are synthesized on a solid support, such as a microarray slide, as described herein.
  • methods and assays of the present invention provide for analysis of single nucleotide polymorphisms (SNPs).
  • the present invention provides methods and assays for analysis of copy number variation (CNV) in DNA samples, for example genomic DNA samples.
  • SNP and CNV analysis is useful in association studies, for example between different species and between SNPs and CNVs associated with diseases and disorders.
  • methods and assays of the present invention provide for the analysis of genomic variation and their association with diseases in a particular subject, for example a human subject.
  • the present invention is not limited to analysis of genomic sequences from any particular genus and/or species, for example any prokaryotic or eukaryotic sequence is considered amenable to applications of the present invention, for research, diagnostic or therapeutic use.
  • the present invention is not limited to a particular set of hybridization conditions.
  • stringent hybridization conditions as known to those skilled in the art are preferably employed.
  • Hybridization solutions of use with the present invention include, but are not limited to, those found in NimbleGen Hybridization Kits (Roche NimbleGen, Madison WI).
  • the present invention provides washing the probe/target complexes following enzymatic cleavage and ligation reactions thereby removing unbound and non- specifically bound nucleic acid molecules.
  • the present invention provides washes of differential stringency, for example a wash buffer I comprising 0.2x SSC, 0.2 % (v/v) SDS, and O.lmM DTT, a wash buffer II comprising 0.2x SSC and O.lmM DTT and a wash buffer III comprising 0.5x SSC and O.lmM DTT.
  • solutions and buffers for washing, hybridization, and enzymatic reactions comprise lithium.
  • the present invention is not limited by composition of the hybridization and/or wash buffers.
  • the target sequences are eluted from the probes following, for example RE digestion, using, for example, water or similar low solute solutions known to those skilled in the art.
  • the present invention provides capture of target nucleic acid sequences for subsequent use in targeted array-based-, shotgun-, capillary-, or other sequencing methods known to the art.
  • sequencing by synthesis is understood to be a sequencing method which monitors the generation of side products upon incorporation of a specific deoxynucleoside-triphosphate during the sequencing reaction (Ronaghi, M., et al., Science 281 (1998) 363-65; incorporated herein by reference in its entirety).
  • one or the more prominent embodiments of the sequencing by synthesis reaction is the pyrophosphate sequencing method.
  • the 454 Genome Sequencer System (Roche Applied Science cat. No. 04760085001) is based on the pyrophosphate sequencing technology.
  • the average genomic DNA fragment size is preferably in the range of 200 or 600 bp, respectively.
  • Sequencing by synthesis reactions can also comprise a terminator dye type sequencing reaction.
  • the incorporated dNTP building blocks comprise a detectable label, such as a fluorescent label, that prevents further extension of the nascent DNA strand.
  • the label is removed and detected upon incorporation of the dNTP building block into the template/primer extension hybrid, for example, by using a DNA polymerase comprising a 3' -5' exonuclease or proofreading activity.
  • a DNA polymerase comprising a 3' -5' exonuclease or proofreading activity.
  • the present invention is not limited by the type of downstream application that may used in conjunction with the present invention.
  • the target sequences are released from the oligonucleotide probe by enzymatic digest (e.g., restriction endonuclease, UDG and Endo VIII, etc.) and eluted away from the probe and sequenced.
  • the sequencing is performed using a 454 Life Sciences Corporation sequencer.
  • the present invention provides target sequence amplification following elution by emulsion PCR (emPCR) following manufacturer's protocols.
  • the beads comprising the clonally amplified target nucleic acids from the emPCR are transferred into a picotiter plate according to the manufacturer's protocol and subjected to a pyrophosphate sequencing reaction for sequence determination.
  • the present invention provides methods and assays wherein a plurality of different target sequences is contemplated for detection on one array or in one solution, for example for concurrent capture and detection of multiple target sequences.
  • a two color labeling is contemplated (e.g., two channel fluorescence, fluorescent/non-fluorescent, etc.).
  • one target sequence is labeled with one detectable moiety and another target sequence is labeled with a second detectable moiety.
  • one target sequence is labeled with a fluorescent moiety (e.g., fluorescein, Cy-3, Cy-5, etc.) and the second target sequence is labeled with a non-fluorescent moiety (e.g., biotin, digoxygenin) or a fluorescent moiety differing in wavelength detection from the first fluorescent moiety.
  • Terminal transferase can be used to 3' end label the target sequences by using, for example, ddCTP conjugates of the fluorophore (e.g., fluorescein- 12-ddCTP) and the second moiety (e.g., biotin- 11-ddCTP).
  • dual channel detection or differential moiety detection allows for differentiation between two different captured target sequences.
  • the signal detected upon completion when practicing methods and assays of the present invention as described herein are further amplified.
  • Examples of signal amplification methods include, but are not limited to, those found in Tyramide Signal Amplification kits commercially available through, for example NEN® Life Sciences Products, Inc. (Boston MA).
  • data analysis is performed on the bound target sequences. Data analysis is performed, for example, to identify a SNP or CNV as found in a captured target sequence. Data analysis is performed using any array scanner, for example an Axon GenePix 4000B fluorescent scanner. Once data is captured by the scanner, bioinformatics programs are utilized to analyze the captured data.
  • Bioinformatics programs useful in data analysis from fluorescent microarray formats include, but are not limited to SignalMapTM (NimbleGen) and NimbleScanTM (NimbleGen) however any scanner and bioinformatics programs capable of capturing and analyzing data generated by the methods of the present invention are equally amenable. Data output is visualized on, for example, any computer screen or other device capable of displaying data generated when practicing the present invention.
  • kits for practicing methods and assays as described herein.
  • the kits comprise reagents and/or other components (e.g., buffers, instructions, solid surfaces, containers, software, etc.) sufficient for, necessary for, performing target nucleic acid capture of target nucleic acid molecules as herein described.
  • Kits are provided to a user in one or more containers (further comprising one or more tubes, packages, etc.) that may require differential storage, for example differential storage of kit components/reagents due to light, temperature, etc. requirements particular to each kit component/reagent.
  • a kit comprises one or more solid supports, wherein said solid support is a microarray slide or a plurality of beads, upon which are affixed a plurality of oligonucleotide capture probes.
  • a kit comprises oligonucleotide probes in solution, wherein said probes comprise a capture moiety, and beads, wherein said beads are designed to bind to the capture moiety as affixed to the oligonucleotide probe.
  • a moiety is a biotin label which can be used for immobilization on a streptavidin coated solid support.
  • such a modification is a hapten like digoxygenin, which can be used for immobilization on a solid support coated with a hapten recognizing antibody.
  • the kit of the present invention comprises at least one or more compounds and reagents for performing enzymatic reactions, for example one or more of a flap endonuclease, a DNA ligase, a RecJ exonuclease, a ssDNA binding protein, a T4 polynucleotide kinase, a restriction endonuclease, a DNA polymerase, a terminal transferase, Kl enow, etc.
  • a kit comprises one or more of hybridization solutions, wash solutions, and/or elution reagents.
  • wash solutions found in a kit include, but are not limited to, Wash Buffer I (0.2x SSC, 0.2 % (v/v) SDS, 0.ImM DTT), and/or Wash Buffer II (0.2x SSC, 0.ImM DTT) and/or Wash Buffer III (0.5x SSC, O.lmM DTT).
  • one or more buffers or solutions as found in the kit comprise lithium.
  • a kit comprises one or more elution solutions, wherein said elution solutions comprise purified water and/or a solution containing TRIS buffer and/or EDTA, or other low solute solution.
  • Experiments were designed to test for ligation efficiencies in methods and assays of the present invention. Experiments were designed utilizing 3' labeled CPK6 oligonucleotides (Integrated DNA Technologies (IDT), Coralville IA) and PCR fragments amplified from E. coli genomic DNA (ATCC No. 700926D-5) yielding amplicons from around 1100 to around 1500 bps (SEQ ID NO: 2, 3 and 4).
  • IDTT Integrated DNA Technologies
  • IA Integrated DNA Technologies
  • Oligonucleotide probes of 50 and 60 mers were designed that comprised a 16 bp hairpin.
  • the hairpin sequence used was 5'-CCGGAGGATACTCCGG-3' (SEQ ID NO:
  • Control probes were synthesized that did not contain hairpin structures.
  • a quartet of probes was designed representing all four bases per strand, as such eight total probes were designed (e.g., 4 for each strand of the DNA target) for the target nucleotide within the query sequence.
  • Each quartet per strand contained the same probe sequence except the terminal base on the 3 ' end of the
  • Probes were synthesized in situ at Roche NimbleGen (Madison,
  • WI on an array with a density of 2.1 million probes per array (HD2).
  • PCR amplification conditions included initial denaturation at 94 0 C for 2 min followed by 30 cycles of 94 °C/30 seconds, 55 °C/60 seconds, 72 0 C 60, with a final elongation of 72 °C for 7 minutes.
  • the fragments were digested with two restriction enzymes (Hhal and NIaIII) yielding fragments of various sizes with 3 ' overhangs.
  • the restriction fragmented amplicons were pooled in equimolar concentrations and further treated with antarctic phosphatase (NEB) to dephosphorylate 5' end. This prevents self-self ligation and direct non-specific ligation to the probes synthesized on the array.
  • NEB antarctic phosphatase
  • Fragmented and dephosphorylated amplicons were labeled with Cy3-ddCTP on their 3' ends with terminal transferase (TdT, Roche) and precipitated away from non-labeled fragments using methods known to those skilled in the art, for example as found in Molecular Cloning, A Laboratory Manual, Eds. Sambrook et al., Cold Spring Harbor Press (incorporated herein by reference in its entirety). Labeled fragments were combined with phosphorylated CPK6 oligonucleotides that were labeled on the 3' end with Cy3 (IDT).
  • IDTT terminal transferase
  • microarray slides were sealed with NimbleChip HX3 mixers (Roche NimbleGen, Madison WI). Denatured and labeled target amplicons were applied to a microarray. Probes found on the microarray included those with and without a hairpin.
  • the microarray slides with target sequences were allowed to hybridize overnight at 42 °C in a MAUI Hybridization System (BioMicro) under stringent conditions, washed three times with wash buffer and scanned. Ligation was performed using Ampligase® (Epicentre, Madison WI) in appropriate buffer and incubation was carried out at 45 °C for 4 hours. The slides were washed three times and the arrays boiled in water with constant stirring for approximately 2 minutes.
  • microarray slides were washed and scanned. Scanning was performed using an Axon GenePix 4000B fluorescent scanner. Data captured for each scan and data analysis was performed using SignalMapTM (NimbleGen) and
  • NimbleScanTM (NimbleGen) software applications.
  • Results demonstrate that for probes with no hairpins (CPK6 control) there was no target capture ( Figure 4). However, when the probe comprised a hairpin and the target fragment sequence comprised the complementary target base, the ligase ligated the target sequence to the probe.
  • the target sequence capture was specific to the identity of the terminal base at the 5' end of each restriction fragment, such that for each quartet of probes representing a query base for a partial fragment of sequence, only one of the four probes has a ligated labeled fragment. This results in high signal intensity for the correct ligation probe in comparison to the background intensity of the remaining three bases in the quartet per strand.
  • the signal intensities associated with the probe with the correct base perfectly identified the sequence based prediction for locations of restriction sites for Hhal and NIaIII.
  • Experiments were designed to test for flap endonuclease and ligation efficiencies in methods and assays of the present invention.
  • Experiments were designed utilizing a 3' labeled CPK6 oligonucleotides (IDT) and PCR fragments amplified from E. coli genomic DNA as described in Example 1.
  • Oligonucleotide probes of 50 and 60 mers were designed that comprised a 16 bp hairpin and a complementary base on the terminal 3' end.
  • the hairpin sequence used was 5 'CCGG AGGAT ACTCCGG3' (SEQ ID NO: 1). Control probes were synthesized that did not comprise hairpin structures.
  • Probes were synthesized in situ at Roche NimbleGen (Madison, WI) on an array with a density of 2.1 million probes per array (HD2).
  • PCR fragments were amplified from genomic E. coli DNA using PCR primers and conditions as previously described.
  • the fragments were digested with two restriction enzymes (Hhal and NIaIII) yielding fragments of various sizes with 3' overhangs.
  • the restriction fragmented amplicons were pooled in equimolar concentrations and further treated with antarctic phosphatase (NEB) to dephosphorylate 5' end. This prevents self-self ligation and direct non-specific ligation to the probes synthesized on the array.
  • NEB antarctic phosphatase
  • Fragmented and dephosphorylated amplicons were labeled with Cy3-ddCTP on their 3' ends with terminal transferase (TdT, Roche) and precipitated away from non-labeled fragments using methods known to those skilled in the art, for example as found in Molecular Cloning, A Laboratory Manual, Eds. Sambrook et al., Cold Spring Harbor Press (incorporated herein by reference in its entirety). Labeled fragments were combined with dephosphorylated CPK6 oligonucletides that were labeled on the 3' end with Cy3 (IDT).
  • IDTT terminal transferase
  • microarray slides were sealed with NimbleChip HX3 mixers (Roche NimbleGen, Madison WI) and denatured, labeled target amplicons were applied to a microarray. Probes found on the microarray included those with and without a hairpin.
  • the microarrays slides with target sequences were allowed to hybridize overnight at 42 °C in a MAUI Hybridization System (BioMicro) under stringent conditions, washed three times with wash buffer and scanned.
  • Cleavase enzyme in appropriate buffer (10 raM MOPs: pH 7.5, 100 mM LiCl, 4 mM MgC12 ) was added to the microarray slides with the bound target sequences and the reactions were incubated at 45 °C for 1 hour, washed three times with wash buffer and scanned. Ligation was performed using Ampligase® (Epicentre, Madison WI) in appropriate buffer and incubation was carried out at 45 °C for 4 hours. The slides were washed three times and the arrays boiled in water with constant stirring for approximately 2 minutes. After boiling, the microarray slides were washed and scanned. Scanning was performed using an Axon GenePix 4000B fluorescent scanner. Data captured for each scan and data analysis was performed using SignalMapTM (NimbleGen) and NimbleScanTM (NimbleGen) software applications.
  • SignalMapTM SignalMapTM
  • NimbleScanTM NimbleScanTM
  • Results demonstrate that for probes with no hairpins (CPK6 control), there was no target capture.
  • the FEN and ligase enzymes cleaved the target sequence and ligated the target to the probe (respectively).
  • the target sequence capture was specific to the identity of the complement base such that for a quartet of probes representing a query base for a partial fragment of sequence, only one of the four probes had a ligated labeled fragment after cleavase reaction. This results in high signal intensity for the correct base call in comparison to the background intensity of the remaining three bases in the quartet per strand ( Figure 5).
  • the fold differences between correct and incorrect base within the quartet were calculated as the ratio between the signal intensity of the correct base call by the average of three incorrect bases.
  • gDNA human and E. coli genomic DNA
  • Oligonucleotide probes were designed as described in Example 1 , such that probes were synthesized in situ at Roche NimbleGen (Madison, WI) at a density of 2.1 million probes per array (HD2).
  • Genomic DNA (gDNA) was fragmented either with sonication or randomly amplified using Klenow fragment with random primers of various lengths (9 mers, 10 mers, 12 mers, and 15 mers) yielding amplified target sequences of differential lengths.
  • the fragments were treated with antarctic phosphatase and labeled with Cy3-ddCTP on their 3' ends using terminal transferase (TdT) and precipitated away from non-labeled fragments using methods known to those skilled in the art.
  • TdT terminal transferase
  • the microarray slides were sealed with HX3 mixers (NimbleGen Roche) and denatured, labeled target sequences were applied to a microarray (5-30 ⁇ g sample/subarray). Probes found on the microarray included those with and without a complement base immediately after the hairpin on their 3' ends, as well as probes with no hairpins.
  • the microarray slides with target sequences were allowed to hybridize overnight at 42 °C, washed three times with wash buffer and scanned.
  • Cleavase enzyme in appropriate buffer was added to the microarray slides with the bound target sequences and the reactions were incubated at 42 °C for 1-2 hours, washed three times with wash buffer and scanned. Ligation was performed using Ampligase® (Epicentre, Madison WI) in appropriate buffer and incubation carried out at 45 °C for 4 hours. The slides were washed three times and the arrays boiled in water with constant stirring for approximately 2 minutes. After boiling, the microarray slides were washed and scanned using an Axon GenePix 4000B fluorescent scanner. Data captured by the scanner and data analysis was performed using SignalMapTM (Roche NimbleGen, Inc.) and NimbleScanTM (Roche NimbleGen, Inc.) software applications.
  • SignalMapTM Roche NimbleGen, Inc.
  • NimbleScanTM Roche NimbleGen, Inc.
  • cleavase enzymes were evaluated for efficacy in the cleavase reactions; arbitrarily named C1-C5, P1-P3 and F1-F12.
  • the cleavase enzymes were furnished by Third Wave Technologies (Madison, WI 53719). Ampligase® (Epicentre, Madison WI).
  • Two microarray slides, each containing 12 identical subarrays were utilized for each experiment to cover all of the 20 cleavases assayed, the probes of which were synthesized by MAS using reverse chemistry (synthesis 5 '-3' where the 5' end of probe was proximal to the substrate) and each of the 12 subarrays contained approximately 120,0000 probes.
  • the probes were designed to represent three different PCR fragments, sense and antisense strand for each of the three fragments.
  • Each probe was designed with sequence specificity correlating to the target amplicon sequences and a 16 bp hairpin (sequence of 5'- CCGGAGGAT ACTCCGG-3' (SEQ ID NO: 1 as seen in Figure 3) with a 3' overhang representing an A, C T or G for both the sense and antisense strand (therefore, 8 probes per PCR fragment) for the target nucleotide within the query sequence.
  • Control probes were synthesized that did not comprise hairpin structures.
  • Fragmented and dephosphorylated amplicons were labeled with Cy3-ddCTP on their 3' ends with terminal transferase (TdT, Roche) and precipitated away from non-labeled fragments using methods known to those skilled in the art, for example as found in Molecular Cloning, A Laboratory Manual, Eds. Sambrook et al., Cold Spring Harbor Press (incorporated herein by reference in its entirety).
  • Target nucleic acids were denatured and applied to the subarray on the microarray slides.
  • the microarrays slides with target sequences were allowed to hybridize overnight at 42 0 C in a MAUI Hybridization System (BioMicro) under stringent conditions, washed three times with wash buffer and scanned.
  • microarray slides were again washed and scanned. Scanning was performed using an Axon GenePix 4000B fluorescent scanner. Data captured for each scan and data analysis was performed using SignalMapTM (Roche NimbleGen, Inc.) and NimbleScanTM (Roche NimbleGen, Inc.) software applications.
  • Figure 7 demonstrates the efficacy of the cleavase/ligase combination in determining genetic sequence of, in this case, a PCR fragment wherein the target sequence had a "C" in the interrogation position.
  • Figure 8 demonstrates that as the length of the 5' end of the bound target fragment increases (e.g., flap length increases), an increase in incorrect base calling occurs. Base calling, or discrimination at a single nucleotide, can be determined by the calculation:
  • a low discrimination score denotes increased confidence for a correct base call and typically as the flap length increases so does the discrimination score, as such so does the incidence of incorrect base calling.
  • Figure 8 demonstrates this phenomenon as exemplified with twelve of the difference cleavase molecules evaluated using 50bp flap length as point of reference and ⁇ 0.5D score as correct base calling.
  • Example 4 Three PCR fragments as described in Example 4 were utilized to evaluate the ability of RecJ to increase the activity of cleavases for digesting longer 5' target flap ends. Experimental parameters as found in Example 4 were followed with the following exception. After the overnight hybridization and stringency washes, approximately 120 Units of RecJf (New England Biolabs, Ipswitch MA; a recombinant fusion protein of Red and a maltose binding protein (MBP) which retains the same enzymatic properties as wild-type RecJ (MBP added to enhance RecJ solubility)) in RecJ buffer was added to the arrays followed by incubation at 37 °C for 1 hour. Addition of a cleavase and thermostable ligase were as previously described. Arrays were analyzed as previously described.
  • RecJf New England Biolabs, Ipswitch MA; a recombinant fusion protein of Red and a maltose binding protein (MBP) which retains the same enzymatic properties as wild
  • RecJ in conjunction with a cleavase enzyme greatly increased the activity of the cleavase.
  • treatment of the hybridized complexes with cleavase in conjunction with RecJ increased the activity of the cleavase as compared to treatment with cleavase without RecJ ( Figure 9A).
  • RecJ Without RecJ as the flap length increased the incidence of incorrect base calling increased as previously demonstrated, such that a flap length of greater than approximately 45 bp led to an increased D score.
  • the cleavase activity was maintained due to the activity of RecJ on the target flap overhang, with resultant D scores of around 0.5 or lower resulting in an increase in correct base calls.
  • the inclusion of RecJ in conjunction with a cleavase greatly improves the incidence of correct base calling in a target sample regardless of the length of the target flap overhang.
  • the interrogation nucleotide By positioning the interrogation nucleotide as described, the cleavase lends specificity as its activity for detecting and cleaving tripartite structures and the ligase will ligate those cleaved products where the interrogation nucleotide is hybridized to its complement. As such, it is contemplated that a dual specificity is provided resulting in a decrease in false positive base calling of a sample.
  • Figure 10 illustrates a comparison of hairpin configuration for single vs. dual enzymatic specificity in cleavase and ligase reactions.
  • Hairpin configuration has an oligomer probe synthesized from 5'-3' with a hairpin of stem-length (e.g., 6 bp - 12 bp) with a 1 bp overhang on the 3' end (Figure 1OA, C).
  • stem-length e.g., 6 bp - 12 bp
  • Figure 1OA, C For each query base, 4 probes are synthesized with hairpins with a single base pair overhang, each representing A, C, T and G.
  • the 3' end of the probe sequence also complements the overhang on the 3' end of the hairpin.
  • Hairpin configuration in Figure 1OB D has an oligomer probe synthesized from 5'-3' with a hairpin of stem-length (e.g., 6 bp - 12 bp).
  • stem-length e.g. 6 bp - 12 bp.
  • 4 probes are synthesized where the last base pair of the hairpin sequence is designed such that it is complementary to the (query base +1) of a known target sequence.
  • all four probes have an identical hairpin sequence, but differ in the terminal 3 ' end base of the oligomer probes and are synthesized to represent A, C, T and G before synthesis of the hairpin. These generate base-specific substrates for ligation between the 3' end of the hairpin and the 5' end of the cleaved target.
  • the interrogation nucleotide is positioned immediately prior to the hairpin structure on the 5 '-side or arm of the probe.
  • the proximal nucleotide is about 2, 3, 4, 5, 6, 7, 8, 9, or 10 bases upstream of the double stranded hairpin structure on the 5' side.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present disclosure provides methods and systems for sequence specific nucleic acid target capture comprising enzymatic reactions. The present disclosure relates to a plurality of oligonucleotide probes for capture and subsequent detection of target nucleic acid sequences, using flap endonucleases, ligases, and/or additional enzymes, proteins or compounds, on substrates, for example microarray slides, and in solution formats.

Description

Methods and Assays for Capture of Nucleic Acids
Field of the invention
The present invention provides methods and systems for sequence specific nucleic acid target capture comprising enzymatic reactions. In particular, the present invention comprises a plurality of oligonucleotide probes for capture and subsequent detection of target nucleic acid sequences, using flap endonucleases, ligases, and/or additional enzymes, proteins or compounds on substrates, for example microarray slides, and in solution formats.
Background of the invention
The advent of nucleic acid microarray technology makes it possible to build an array of millions of nucleic acid sequences in a very small area, for example on a microscope slide (e.g., US 6,375,903 and US 5,143,854). Initially, such arrays were created by spotting pre-synthesized DNA sequences onto slides. However, the construction of maskless array synthesizers (MAS) as described in US 6,375,903 now allows for the in situ synthesis of oligonucleotide sequences directly on the slide itself.
Using a MAS instrument, the selection of oligonucleotide sequences to be constructed on the microarray is under software control such that it is now possible to create individually customized arrays based on the particular needs of an investigator. In general, MAS-based oligonucleotide microarray synthesis technology allows for the parallel synthesis of over 4 million unique oligonucleotide features in a very small area of a standard microscope slide. With the availability of the entire genomes of hundreds of organisms, for which a reference sequence has generally been deposited into a public database, microarrays have been used to perform sequence analysis on nucleic acids isolated from a myriad of organisms.
Nucleic acid microarray technology has been applied to many areas of research and diagnostics, such as gene expression and discovery, mutation detection, allelic and evolutionary sequence comparison, genome mapping, drug discovery, and more. Many applications require searching for genetic variants and mutations across the entire human genome; variants and mutations that, for example, may underlie human diseases. In the case of complex diseases, these searches generally result in a single nucleotide polymorphism (SNP) or set of SNPs associated with one or more diseases. Identifying such SNPs has proven to be an arduous, time consuming, and costly task wherein resequencing large regions of genomic DNA, usually greater than 100 kilobases (Kb) from affected individuals and/or tissue samples is frequently required to find a single base change or identify all sequence variants.
The genome is typically too complex to be studied as a whole, and techniques must be used to reduce the complexity of the genome. To address this problem, one solution is to reduce certain types of abundant sequences from a DNA sample, as found in US 6,013,440. Alternatives employ methods and compositions for enriching genomic sequences as described, for example, in Albert, T.J., et al., Nat. Meth., 4 (2007) 903-5; incorporated herein by reference in its entirety) and Okou, D.T., et al., Nat. Meth. 4(11) (2007) 907-9; incorporated herein by reference in its entirety) and US Patent Application Numbers 11/789,135, 11/970,949, 61/032,594 and 61/026,592; all of which are incorporated herein by reference in their entireties, disclosing alternatives that are cost-effective and rapid in effectively reducing the complexity of a genomic sample in a user defined way to allow for further processing and analysis.
However, methods in use suffer from low signal-to-noise ratios and reproducibility issues. As such, what are needed are methods and systems that allow for, for example, improvements in signal-to-noise, increase in the reproducibility from assay to assay, specific sequence capture, all while remaining quantitative. Such methods would provide maximum data utility to investigators in their endeavors to understand and identify causes of disease and associated therapeutic treatments.
Summary of the invention
The present invention provides methods and systems for sequence specific nucleic acid target capture comprising enzymatic reactions. In particular, the present invention comprises a plurality of oligonucleotide probes for capture and subsequent detection of target nucleic acid sequences, using flap endonucl eases, ligases, and/or additional enzymes, proteins or compounds on substrates, for example microarray slides, and in solution formats.
Certain illustrative embodiments of the invention are described below. The present invention is not limited to these embodiments. In embodiments of the present invention, oligonucleotide probes are synthesized in situ, or synthesized and spotted onto a substrate, wherein said probes affixed to a substrate (e.g., microarray slide, bead, microsphere) and comprise a single stranded 5' end complementary to target sequence, and a 3' end comprising a hairpin structure and a terminal base complementary to a target nucleotide. In other embodiments of the present invention, probes are synthesized comprising a single stranded 5' end further comprising a binding moiety, for example a biotin, attached to the 5' end of the probe, and a 3' end comprising a hairpin structure and terminal base complementary to a target sequence, and the probes are maintained in solution. In some embodiments, the hairpin structure as found in the probe comprises a sequence that is recognized and cleaved by a restriction endonuclease (RE). In some embodiments of the present invention, target nucleic acids include for example, genomic DNA or derivatives thereof, RNA, cDNA, microRNA (miRNA), noncoding RNA (ncRNA), promoter-associated small RNA (PASR), and the like are added to interact with the probes.
In some embodiments, the nucleic acids are fragmented, for example by shearing, whereas in other embodiments nucleic acid targets are amplified, for example with PCR or by Klenow. In preferred embodiments, the target nucleic acids are labeled at the 3' end with a detectable moiety following fragmentation or amplification, for example a fluorescent, biotin, digoxygenin, etc. moiety. The present invention is not limited by the detection moiety and/or method used, and it is contemplated that a skilled artisan will understand the myriad options of detection moieties that can be attached to the 3' ends of nucleic acids for detection purposes. In some embodiments, the target nucleic acid sequences are at least 100 bp, at least 200 bp, at least 300 bp, at least 400 bp, at least 500 bp, at least 600 bp long. However, the present invention is not limited to the size of the target nucleic acid sequences, and non-fragmented as well as fragmented and derived nucleic acid samples (e.g., PCR amplicons, Klenow random primed amplicons, etc.) are contemplated for use with methods and assays of the present invention. In some embodiments, the target nucleic acid sequence comprises a single nucleotide polymorphism or a copy number variation.
In some embodiments, an interrogation nucleotide is positioned after the hairpin structure and at the 3 ' end of the probe. In some embodiments, the interrogation nucleotide is positioned, for example, immediately prior to the hairpin structure on the 5' side and the 3' end of the probe is designed to be complementary to a known target sequence. In some embodiments, the proximal nucleotide is 2, 3, 4, 5, 6, 7, 8, 9, or 10 bases upstream of the double stranded hairpin structure on the 5' side. In some embodiments, by positioning the interrogation nucleotide on the 5' side or arm of the probe sequence, a dual specificity with regards to both the cleavase and the ligase enzymes is realized as compared to cleavase specificity alone. In some embodiments, when the interrogation nucleotide is positioned on the 5' side as described, the cleavase specificity depends on the tripartite structures and a base specific substrate for ligation between the 3' end of the hairpin and the 5' end of the cleaved target.
In some embodiments, labeled target nucleic acids are incubated with the probes, either on the substrate or in solution, under conditions suitable for hybridization to occur. Following hybridization, target sequences that are complementary to the terminal 3' nucleotide of the probe create a sequence specific structure that is recognized and cleaved by a flap endonuclease (FEN). A ligase enzyme, in preferred embodiments, a thermostable ligase enzyme, is added to the reaction for ligating the 3' end of the probe to the 5' end of the cleaved target nucleic acid, thereby covalently linking the target nucleic acid to the probe. If the target sequence is not complementary to the 3 ' terminal nucleotide on the probe, then no cleavage structure is formed, no cleavage by the flap endonuclease occurs, and ligation cannot proceed. In some embodiments, the enzymatic reactions occur sequentially by adding the FEN to hybridized probe/target complexes, followed by separate addition of the ligase. In other embodiments, the FEN and ligase are added at the same time such that the reactions have the opportunity to occur more or less simultaneously. In some embodiments, RecJ exonuclease is added to the reaction in conjunction with a cleavase. In some embodiments, a ssDNA binding protein is additionally added to the reaction. The present invention is not limited to a particular mechanism. Indeed, an understanding of the mechanism is not necessary to practice the present invention. Nonetheless, it is contemplated that the addition of RecJ and/or a ssDNA binding protein in conjunction with a FEN provides for enhanced activity of the cleavase in that the exonuclease activity of the RecJ in degrading long overhangs of hybridized target fragments provides for substrates more suitable for optimal cleavase activity compared to reactions when RecJ and/or a ssDNA binding are absent.
In some embodiments wherein the probe is affixed to a substrate, for example a microarray slide, the non-specifically bound nucleic acid molecules are washed away from the covalently bound target molecules. In some embodiments wherein the labeled probes are maintained in solution, the labeled probes with the covalently bound target molecules are captured by a substrate, for example a bead, slide, plate, etc. coated with capture molecules. For example, if the probe is biotin labeled then beads coated with streptavidin capture the probe/target complex thereby separating the bound target molecules from the non-bound molecules. In some embodiments, the substrates are washed to further purify the captured, target molecules away from the non-specifically bound nucleic acid molecules.
In some embodiments, the substrate comprising the covalently bound targets is scanned using a fluorescent scanner, for example, to detect the fluorescent moiety found on the target sequence, and data containing sequence information is communicated to a user, for example via a computer or other visualization means.
In some embodiments, the bound target nucleic acids are released from the substrate for downstream applications such as sequencing. For example, in some embodiments the hairpin structure of the probe comprises one or more restriction endonuclease sites or uracils. The present invention is not limited to any particular cleavable sequence, and a skilled artisan will recognize the myriad of options that are amenable to methods and assays of the present invention. Once the target nucleic acid is captured, covalently bound to the probe, and separated from non- specifically bound nucleic acid molecules as described herein, the target sequence is released from the probe by digesting the probe/target complex with a RE, or uracil-DNA-glycosylase followed by endonuclease VIII digestion, wherein the sequence recognized by the RE is found in the hairpin structure of the probe or uracils were synthesized into the probe hairpin. Once released, the target sequences are eluted from the probe using methods known to those skilled in the art, for example by incubating the target sequence/probe complexes in water or a low solute solution. The eluted target molecules are applied to downstream applications, for example sequencing reactions.
Methods and assays of the present invention as described herein find utility, for example, in detecting single nucleotide polymorphisms, genomic copy number variations, and the like. Genomic anomalies can be studied for their association with diseases and disorders, thereby providing insight into the causes of diseases and disorders for research and diagnostic purposes, as well as providing potential targets for use in drug discovery in identifying therapeutic treatments for such diseases and disorders. In some embodiments, the present invention provides a method for capturing target nucleic acid sequences comprising providing a nucleic acid sample wherein said sample comprises a detection moiety, preferably a fluorescent moiety such as Cy-3, and may or may not comprise a target sequence, at least one flap endonuclease, at least one ligase, preferably a thermostable ligase, and a plurality of oligonucleotide probes, wherein said probes comprise target sequences and a hairpin structure, applying said nucleic acid sample to said oligonucleotide probes under conditions for hybridization to occur, applying said flap and ligase enzymes to said hybridized nucleic acid/probe complex under conditions allowing for enzymatic reactions to occur thereby capturing said target nucleic acid sequences. In preferred embodiments, RecJ exonuclease and a ssDNA binding protein are included in the reaction in conjunction with a flap endonuclease. In some embodiments, the nucleic acid sample is a genomic DNA sample or a derivative thereof, wherein said sample is from a mammal, preferably a human. In some embodiments, at least one of said target sequences includes a single nucleotide polymorphism, while in other embodiments the target sequence is a genomic copy number variant. In some embodiments, the hairpin structure comprises SEQ ID NO: 1. In some embodiments, the captured target nucleic acids are further detected, for example using a fluorescent scanner. In some embodiments, the probes are affixed to a substrate, for example a microarray slide, while in other embodiments the probes are maintained in solution. In some embodiments, the probes are associated with gel pads.
In some embodiments, the present invention provides a method for capturing target nucleic acid sequences comprising providing a nucleic acid sample wherein said sample comprises a detection moiety, preferably a fluorescent moiety such as, for example, Cy-3, and may or may not comprise a target sequence, at least one flap endonuclease, at least one ligase, preferably a thermostable ligase, and a plurality of oligonucleotide probes, wherein said probes comprise target sequences and a hairpin structure wherein said hairpin structure comprises cleavable sequences, providing conditions for hybridization to occur between the probes and the target nucleic acids, applying said flap and ligase enzymes to said hybridized nucleic acid/probe complex under conditions allowing for enzymatic reactions to occur thereby capturing said target nucleic acid sequences. In preferred embodiments, RecJ exonuclease and a ssDNA binding protein are included in the reaction in conjunction with a flap endonuclease. In some embodiments, the cleavable sequences comprise a restriction endonuclease site, recognized and cleavable by a restriction endonuclease. In some embodiments, the target nucleic acids are released from the probes by restriction endonuclease digest followed by sequencing for detection of the target sequences.
In some embodiments, the present invention provides a composition for sequence specific nucleic acid capture on a substrate or in solution comprising a flap endonuclease, a ligase, and oligonucleotide probes wherein said probes comprise a hairpin structure and complementary target nucleic acid sequences. In some embodiments, the oligonucleotide probes are affixed to a substrate, for example a microarray slide or a bead.
In some embodiments, the present invention includes a kit, wherein said kit is used for capturing nucleic acid target sequences comprising at least one flap endonuclease, at least one thermostable ligase, a plurality of oligonucleotide probes affixed to a substrate or in a purified state, and at least one buffer. In preferred embodiments, RecJ exonuclease and a ssDNA binding protein are further included in a kit.
In some embodiments, the oligonucleotide probes consists essentially of a single stranded 5' end complementary to a target sequence, and a 3' end consisting essentially of a hairpin structure and a terminal base complementary to a target nucleotide. In some embodiments, the interrogation nucleotide is positioned on the 5 'side of the probe.
In some embodiments, the present invention includes a kit, wherein said kit is used for capturing nucleic acid target sequences and consists essentially of at least one flap endonuclease, at least one thermostable ligase, a plurality of oligonucleotide probes affixed to a substrate or in a purified state, RecJ exonuclease, a ssDNA binding protein and at least one buffer.
As used herein, the term "sample" is used in its broadest sense. In one sense, it includes a nucleic acid specimen obtained from any source. Biological nucleic acid samples may be obtained from animals (including humans) and encompass nucleic acids isolated from fluids, solids, tissues, etc. Biological nucleic acid sample may also come from non-human animals, including, but are not limited to, vertebrates such as rodents, non-human primates, ovines, bovines, ruminants, lagomorphs, porcines, caprines, equines, canines, felines, aves, etc. Biological nucleic acids may also be obtained from prokaryotes, like bacteria and other non-animal eukaryotes such as plants. It is contemplated that the present invention is not limited by the source of nucleic acids sample, and any nucleic acid from any biological Kingdom finds utility in methods as described herein.
As used herein, the term "nucleic acid molecule" refers to any nucleic acid containing molecule from any sample source, including but not limited to, DNA or RNA. The term encompasses sequences that include any of the known base analogs of DNA and RNA including, but not limited to, 4-acetylcytosine, 8-hydroxy-N6- methyladenosine, aziridinylcytosine, pseudoisocytosine, 5-(carboxyhydroxyl- methyl) uracil, 5-fluorouracil, 5-bromouracil, 5- carboxymethylaminomethyl-2-thiouracil, 5-carboxymethylaminomethyluracil, dihydrouracil, inosine, N6-isopentenyladenine, 1-methyladenine, 1-methylpseudo- uracil, 1 -methylguanine, 1 -methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3 -methyl cytosine, 5-methylcytosine, N6-methyladenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyamino- methyl-2-thiouracil, beta-D-mannosylqueosine, 5 '-methoxycarbonylmethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid, oxybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, N- uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid, pseudouracil, queosine, 2-thiocytosine, and 2,6-diaminopurine.
The used herein, the term "oligonucleotide" refers to a molecule comprised of two or more deoxyribonucleotides or ribonucleotides, preferably more than three, and usually more than ten. The exact size will depend on many factors, which in turn depends on the ultimate function or use of the oligonucleotide. The oligonucleotide may be generated in any manner, including chemical synthesis, DNA replication, reverse transcription, or a combination thereof. The term oligonucleotide may also be used interchangeably with the term "polynucleotide."
As used herein, the terms "complementary" or "complementarity" are used in reference to polynucleotides related by the base-pairing rules. For example, the sequence "5'-A-G-T-3',M is complementary to the sequence "3'-T-C-A-5\" Complementarity may be "partial," in which only some of the nucleic acids' bases are matched according to the base pairing rules. Or, there may be "complete" or "total" complementarity between the nucleic acids. The degree of complementarity between nucleic acid strands has significant effects on, for example, the efficiency and strength of hybridization between nucleic acid strands, amplification specificity, etc. As used herein, the term "hybridization" is used in reference to the pairing of complementary nucleic acids. Hybridization and the strength of hybridization (i.e., the strength of the association between the nucleic acids) is impacted by such factors as the degree of complementary between the nucleic acids, stringency of the conditions involved, the Tm of the formed hybrid, and the G:C ratio within the nucleic acids. While the invention is not limited to a particular set of hybridization conditions, stringent hybridization conditions are preferably employed. Stringent hybridization conditions are sequence-dependent and will differ with varying environmental parameters (e.g., salt concentrations, and presence of organics). Generally, "stringent" conditions are selected to be about 5 °C to 20 °C lower than the thermal melting point (Tm) for the specific nucleic acid sequence at a defined ionic strength and pH. Preferably, stringent conditions are about 5 °C to 10 0C lower than the thermal melting point for a specific nucleic acid bound to a complementary nucleic acid. The Tm is the temperature (under defined ionic strength and pH) at which 50 % of a nucleic acid hybridizes to a perfectly matched probe.
As used herein the term "stringency" is used in reference to the conditions of temperature, ionic strength, and the presence of other compounds such as organic solvents, under which nucleic acid hybridizations are conducted. Under "low stringency conditions" a nucleic acid sequence of interest will hybridize to its exact complement, sequences with single base mismatches, closely related sequences (e.g., sequences with 90 % or greater homology), and sequences having only partial homology (e.g., sequences with 50-90 % homology). Under "medium stringency conditions," a nucleic acid sequence of interest will hybridize only to its exact complement, sequences with single base mismatches, and closely relation sequences (e.g., 90 % or greater homology). Under "high stringency conditions," a nucleic acid sequence of interest will hybridize only to its exact complement, and (depending on conditions such a temperature) sequences with single base mismatches. In other words, under conditions of high stringency the temperature can be raised so as to exclude hybridization to sequences with single base mismatches.
By way of example, "stringent conditions" or "high stringency conditions," comprise hybridization in 50 % formamide, 5x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1 % sodium pyrophosphate, 5x Denhardt's solution, sonicated salmon sperm DNA (50 mg/ml), 0.1 % SDS, and 10 % dextran sulfate at 42 °C, with washes at 42 °C in 0.2x SSC (sodium chloride/sodium citrate) and 50 % formamide at 55 0C, followed by a wash with O.lx SSC containing EDTA at 55 °C. For moderately stringent conditions, it is contemplated that buffers containing 35 % formamide, 5x SSC, and 0.1 % (w/v) sodium dodecyl sulfate are suitable for hybridizing at 45 °C for 16-72 hours. Furthermore, it is contemplated that formamide concentration may be suitably adjusted between a range of 0-45 % depending on the probe length and the level of stringency desired. In some embodiments of the present invention, probe optimization is obtained for longer probes (for example, greater than 50 mers) by increasing the hybridization temperature or the formamide concentration to compensate for a change in the probe length. Additional examples of hybridization conditions are provided in many reference manuals, for example in "Molecular Cloning: A Laboratory Manual", as referenced and incorporated herein.
Similarly, "stringent" wash conditions are ordinarily determined empirically for hybridization of target sequences to a corresponding probe array. For example, the arrays are first hybridized and then washed with wash buffers containing successively lower concentrations of salts, or higher concentrations of detergents, or at increasing temperatures until the signal-to-noise ratio for specific to nonspecific hybridization is high enough to facilitate detection of specific hybridization. By way of example, stringent temperature conditions will usually include temperatures in excess of about 30 °C, more usually in excess of about 37 °C, and occasionally in excess of about 45 °C. Stringent salt conditions will ordinarily be less than about 1000 mM, usually less than about 500 mM, more usually less than about 150 mM. Stringent wash and hybridization conditions are known to those skilled in the art, and can be found in, for example, Wetmur, J. G., and Davidson, M., J MoI Biol 31 (1968) 349-70 and Wetmur, J.G., Crit Rev Bio MoI Biol 26(3/4) (1991) 227-59; incorporated herein by reference in their entireties.
It is well known in the art that numerous equivalent conditions may be employed to adjust and regulate stringency conditions; factors such as the length and nature (DNA, RNA, base composition) of the probe and nature of the target (DNA, RNA, base composition, present in solution or immobilized, etc.) and the concentration of the salts and other components (e.g., the presence or absence of formamide, dextran sulfate, polyethylene glycol) are considered. As such, the components and concentrations of hybridization and wash solutions will vary to generate conditions of stringency. In preferred embodiments of the present invention, hybridization and wash solutions are utilized as found commercially available through Roche- NimbleGen (e.g., NimbleChip™ CGH Arrays, NimbleGen Hybridization Kits, etc.).
As used herein, the term "primer" refers to an oligonucleotide, whether occurring naturally as in a purified restriction digest or produced synthetically, that is capable of acting as a point of initiation of synthesis when placed under conditions in which synthesis of a primer extension product that is complementary to a nucleic acid strand is induced, (i.e., in the presence of nucleotides and an inducing agent such as DNA polymerase and at a suitable temperature and pH). The primer is preferably single stranded for maximum efficiency in amplification, but may alternatively be double stranded. If double stranded, the primer is first treated to separate its strands before being used to prepare extension products. Preferably, the primer is an oligodeoxyribonucleotide. The primer must be sufficiently long to prime the synthesis of extension products in the presence of the inducing agent. The exact lengths of the primers will depend on many factors, including temperature, source of primer and the use of the method.
As used herein, the term "probe" refers to an oligonucleotide (i.e., a sequence of nucleotides), whether occurring naturally as in a purified restriction digest or produced synthetically, recombinantly or by PCR amplification, that is capable of hybridizing to at least a portion of another oligonucleotide of interest. A probe may be single-stranded or double-stranded, however in the present invention the probes are intended to be single stranded. Probes are useful in the detection, identification and isolation of particular gene sequences. Probes, in embodiments of the present invention, comprise a 5' single stranded end and a 3' end comprising a hairpin structure. A restriction endonuclease site may or may not be present in the hairpin structure.
As used herein, the term "derivative thereof of "portion" or "fragment" when in reference to a nucleotide sequence (as in "a derivative thereof of a given nucleotide sequence") refers to fragments of that sequence. The fragments may range in size from four nucleotides to the entire nucleotide sequence minus one nucleotide (10 nucleotides, 20, 30, 40, 50, 100, 200, etc.). Fragments can be obtained through, for example, sonication, PCR amplification, Klenow amplification, or any other means known in the art for reducing a nucleotide sequence to smaller sequences thereof. In the present invention, fragments, derivatives of nucleic acid sequences are preferably at least 200 bp, at least 300 bp, at least 400 bp, at least 500 bp, at least 600 bp. However, the present invention is not limited to the size of the target nucleic acid sequences.
As used herein, the term "purified" or "to purify" refers to the removal of components (e.g., contaminants) and/or contaminants from a sample. The term "purified" refers to molecules, either nucleic or amino acid sequences that are removed from their natural environment, isolated or separated. An "isolated nucleic acid sequence or sample" is therefore a purified nucleic acid sequence or sample. "Substantially purified" molecules are at least 60 % free, preferably at least 75 % free, and more preferably at least 90 % free from other components with which they are naturally associated. In certain embodiments of the present invention, "purified" relates to the separation of unbound sample nucleic acid molecules and reaction components (e.g., enzymes, etc.) away from probe/target complexes, typically by washing with wash buffers of one or more stringencies, thereby "purifying" the probe/target nucleic acid complexes from other reaction components.
As used herein, the term "interrogation nucleotide" refers to the nucleotide in the probe that interacts with (e.g, matching base pair formation or a mismatch) the target sequence to determine a specific mutation such as a single nucleotide polymorphism or for sequence-specific capture of target nucleotides from a sample using a plurality of oligonucleotide probes. In some embodiments, the interrogation nucleotide is positioned as a terminal base at the 3 'end of the probe. In some embodiments, the interrogation nucleotide is positioned on the 5 '-side or arm of the probe (i.e., the single stranded region of the probe), proximal to the hairpin stem structure. In some embodiments, interrogation nucleotide is positioned immediately next to and upstream of the hairpin stem structure. In some embodiments, the proximal nucleotide is 2, 3, 4, 5, 6, 7, 8, 9, or 10 bases upstream of the double stranded hairpin structure on the 5' side. The interrogation nucleotide may also be referred as "allele specific nucleotide". In some embodiments, the interrogation nucleotide, if a corresponding complementary nucleotide is present in the target, creates an overlapping tripartite structure with the target molecule that is recognized by a cleavase.
Description of the figures
Figure 1 shows an exemplary embodiment for the use of flap endonucleases and ligases to cleave and ligate target molecules to probes affixed to a microarray solid support; A) a four probe set for one strand of a target DNA molecule associated with potential target DNA sequences, B) flap endonuclease cleavage of the correct target nucleic acid sequence associated with the complementary probe, with no cleavage of the incorrect target sequence, and C) ligation of the 5' end of the correct target sequence with the 3 ' end of the probe, with the incorrect target sequences not ligated to the probe.
Figure 2 demonstrates an exemplary embodiment for the use of flap endonucleases and ligases to cleave and ligate target molecules to labeled probes in solution; A) sequence specific cleavage followed by ligation of target molecules (SEQ ID NO: 33) to a biotinylated probe (SEQ ID NO: 32) when an invasive complex is formed, and B) capture of labeled probes with covalently attached target molecules to beads coated with streptavidin.
Figure 3 shows an exemplary hairpin sequence of an oligonucleotide probe
(SEQ ID NO: 1) as described herein. Figure 4 shows experimental data of using the present method in capturing
CPK6 target sequences; target sequences are captured by probes with hairpins, FEN cleaved, and ligated to the probe, whereas control sequences are not.
Figure 5 shows experimental data demonstrating the efficiency of methods of the present invention in capturing target sequences (correct vs. incorrect base call), and the fold difference in capturing the correct versus the incorrect target sequence.
Figure 6 demonstrates the three different E-coli amplifications and the restriction digest maps for created fragmented experimental
DNAs.
Figure 7 exemplifies the use of the present invention is identifying genomic mutations.
Figure 8 demonstrates the effect of 5' flap length on the activity of different cleavase molecules with regards to the ability to correctly perform base calling as indicated by low discrimination scores (<0.5 D score). Figure 9 exemplifies the effect of RecJ in enhancing cleavase activity; A) demonstrates cleavase reactions without RecJ and B) demonstrates the enhanced activity of a cleavase in the presence of Red.
Figure 10 illustrates a comparison of hairpin configuration for single vs. dual enzymatic specificity in cleavase and ligase reactions. A, C) Hairpin configurations have, for example, oligomer probes (SEQ
ID NOS: 11-14, 34-37) synthesized from 5'-3' with a hairpin of stem-length (6 bp - 12 bp) with a 1 bp overhang on the 3' end. B, D) Hairpin configurations have, for example, oligomer probes (SEQ ID NOS: 16-19, 38-41) synthesized from 5'-3' with a hairpin of stem-length (6 bp - 12 bp). These generate base specific substrates for ligation between the 3' end of the hairpin and the 5' end of the cleaved targets (SEQ ID NOS: 15, 42). OL refers to overlap at an interrogation site. Therefore, OLl refers to an overlap of 1 nucleotide and OLO refers to zero or no overlap at the interrogation site.
Figure 11 shows the evaluation of specificity of base calling using various hairpin configurations across an 83 bp PCR fragment. Discrimination scores were calculated for every base across the 83 bp fragment and plotted against two classes of hairpin configurations; 1) Dual (OLO) and 2) Single (OLl) enzyme specificity. Within each class, several stem and loop sequences were compared. The control probeset with no hairpins (No HP) had the lowest discrimination, whereas the dual enzymatic hairpin configuration had the highest. Figure 12 shows the evaluation of specificity of base calling using various hairpin configurations across an 83 bp PCR fragment. Discrimination scores were calculated for every base across the 83 bp fragment and plotted against two classes of hairpin configurations; 1) Dual (OLO) (SEQ ID NOS: 20-25) and 2) Single (OLl) (SEQ ID NOS: 26-31) enzyme specificity. Within each class, several stem and loop sequences were compared.
Detailed description of the invention
The present invention provides methods and assays for the use of flap endonucl eases and ligases in methods and assays for targeted capture of nucleic acids on solid substrates and in solution. Certain illustrative embodiments of the invention are described below. The present invention is not limited to these embodiments.
Flap endonucleases (FENs), also known as cleavases, are structure specific enzymes that are capable of cleaving nucleic acids in a sequence specific manner. The enzymes have been used as components in the development of the Invader® genotyping and nucleic acid detection technology from Third Wave Technologies, for example as found in US Patents and Published Patent Applications 5,843,669, 5,888,780, 6,090,606, 6,562,611, 7,122,364, 2007/0003942, 2007/0292856, 2006/0292580, 2006/0183207, 2006/0177835, 2006/0154269 and 2006/0040294, all of which are incorporated herein by reference in their entireties. Additional examples of flap endonuclease compositions and methods are found in US Patents and Published Patent Applications 6,255,081, 6,251,649, 6,979,725, 5,874,283, 2007/0292934, 2007/0292864, 2007/0231815, and 2007/0105138, all of which are incorporated herein by reference in their entireties. The endonuclease activity of FENs includes recognition of a DNA duplex which has a 5' overhang (flap) on one of the strands, called the invasive complex (as exemplified in Figures 1 and 2). The FEN catalyses hydrolytic cleavage of the phosphodiester bond at the junction of the single and double stranded DNA (Harrington, JJ., and Lieber, M.R., EMBO J 13(5) (1994) 1235-46; Harrington, J.J., and Lieber, M.R., J Biol Chem 270(9) (1995) 4503-8; incorporated herein be reference in their entireties). The ability of FENs to recognize and cleave specific secondary structures allows these enzymes to be used to detect internal sequence differences in nucleic acids without prior knowledge of the specific sequence of the nucleic acid. In some embodiments of the present invention, when the 3' terminal nucleotide of the probe is present in the target nucleic acid sample, the specific structure recognized by FENs is created and FEN cleavage occurs. However, when the sequence as found in the probe is not complementary to the target sequence, no structure is realized and FEN cleavage does not occur. As such, sequence specific recognition of target nucleic acids is achieved.
Ligases, in particular thermostable ligases, are further contemplated for use with methods and assays of the present invention. Ligation of the probe 3' end to the 5' end of the target molecule is performed following FEN cleavage of the target molecule, if the FEN recognized structure is present. As known to a skilled artisan, ligases catalyse the formation of covalent phosphodiester bonds between juxtaposed 3' hydroxyl and 5' phosphate termini in duplex DNA or RNA (exemplified in Figures 1 and T). In preferred embodiments of the present invention, thermostable ligases are contemplated. Non-thermostable ligases, such as T4 DNA ligase demonstrate optimal enzymatic activity at room temperature. Thermostable ligases, for example those found in the bacteria Thermus aquaticus and Pyrococcus furiosus, demonstrate optimal enzymatic activity at much higher temperatures, for example greater than 45 °C, allowing more flexibility in temperature conditions when applied to methods and assays of the present invention as described herein. Examples of thermostable ligases are found in, for example, US Patents and Published Patent Applications 6,949,370, 6,576,453, 6,280,998, 6,444,429, 5,700,672, 2007/0037190, 2005/0266487 and European Patent Publication WO 07/035439, all of which are incorporated herein by reference in their entireties. Once FEN has cleaved that target nucleic acid, ligation via a ligase enzyme covalently links the target sequence to the probe, wherein said probe is either affixed to a solid support, for example a microarray slide, or kept in solution. As such, sequence specific capture of a target nucleic acid is achieved.
It was further contemplated that the inclusion of RecJ with or without a ssDNA binding protein (SSBP) would enhance the efficacy of the cleavase once the invasive complex in the described hybridization reaction is recognized by the cleavase. Rec J exonuclease (RecJ) degrades single stranded DNA in the 5 '-3' direction and further participates in mismatch repair and homologous recombination (Lovett, S.T., and Kolodner, R.D., Proc Natl Acad Sci 86 (1989) 2627-2631; Yamagata, A., et al., Nucl Acids Res 29(22) (2001) 4617-4624; Han, E.S., et al., Nucl Acids Res 34(4) (2006) 1084-1091; incorporated herein by reference in their entireties). Rec J degrades both phosphorylated and unphosphorylated DNA ends with equal affinity, however requires that the single stranded end be at least 7 nucleotides long. Rec J is a processive exonuclease and degrades approximately 1000 nucleotides after it binds to the single stranded end, typically stopping when it comes to the double stranded DNA junction. However, RecJ nuclease activity is not precise, and it may stop degradation activity a few nucleotides short of the junction or a few base pairs after the function. It has been suggested that the recruitment of Rec J to the single stranded DNA may be enhanced by the addition of a single stranded DNA binding protein to the degradation reaction (Han, E.S., et al., Nucl Acids Res 34(4) (2006) 1084-1091). As such, the inclusion of one or more of a RecJ exonuclease and a SSBP is contemplated to enhance the cleavase activity allowing for higher efficiencies is sequence specific capture of a target nucleic acid as described herein. In some embodiments, oligonucleotide probes are attached to a solid support, such as a microarray slide, at their 5' ends or 5 'sides or 5' arms, wherein said probes comprise a central portion that is single stranded and complementary to a target sequence, and a 3 ' terminal region that comprises a hairpin structure comprising a loop of single nucleotides bounded by double stranded region of complementary nucleic acids, ending in a 3' terminal base specific to a target sequence of interest (e.g., an interrogation nucleotide for determining a genomic mutation such as single nucleotide polymorphism). In some embodiments, the base that is specific to the target sequence, e.g., for determining a mutation or a polymorphism is placed immediately proximate to the hairpin loop structure on the 5 '-side of the probe. In preferred embodiments, the double stranded hairpin region is at least 3 base pairs, at least 5 base pairs, at least 6 base pairs, at least 8 base pairs, at least 10 base pairs, at least 16 base pairs. The nucleic acid probes are incubated with a complex target population of nucleic acid strands (e.g., DNA, cDNA, gDNA, RNA, mRNA, tRNA, etc.), for example human genome DNA (gDNA) (e.g., whole or fragmented), under conditions that favor hybridization of complementary DNA strands such that nucleic acid sequences complementary to the single stranded portion of the 5' end of the nucleic acid probe and the probe 3' terminal base specifically hybridize to the probe. In some embodiments, the target nucleic acids are labeled on the 3' end with, for example, a detectable moiety (e.g., fluorophore, chromophore, radioisotope, etc.).
In some embodiments, the present invention provides oligonucleotide probes attached to a solid support, such as a microarray slide, at their 5' ends, wherein said probes comprise a central portion that is single stranded and partially complementary to a target sequence, and a 3' terminal region that comprises a hairpin structure comprising a loop of single nucleotides bounded by a double stranded region of complementary nucleic acids, ending in a 3' terminal base complementary to a target sequence, wherein a nucleotide proximal to the 5' end of the double stranded region of complementary nucleic acids that comprise a hairpin structure includes a sequence complementary to a target sequence of interest (e.g., an interrogation nucleotide for determining genomic mutations such as single nucleotide polymorphisms). In preferred embodiments, the proximal nucleotide is immediately proximate to the double stranded hairpin structure. In some embodiments, the proximal nucleotide is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 bases upstream of the double stranded hairpin structure on the 5' side. In preferred embodiments, the double stranded hairpin region is at least 3 base pairs, at least 10 base pairs, at least 16 base pairs. The nucleic acid probes are incubated with a complex target population of nucleic acid strands (e.g., DNA, cDNA, gDNA, RNA, mRNA, tRNA, etc.), for example human genome DNA (gDNA) (e.g., whole or fragmented), under conditions that favor hybridization of complementary DNA strands such that nucleic acid sequences complementary to the single stranded portion of the 5' end of the nucleic acid probe and the probe 3' terminal base specifically hybridize to the probe. In some embodiments, the target nucleic acids are labeled on the 3' end with, for example, a detectable moiety (e.g., fluorophore, chromophore, radioisotope, etc.).
In some embodiments, the present invention provides oligonucleotide probes attached to a solid support, such as a microarray slide, at their 5' ends, wherein said probes comprise a central portion that is single stranded and complementary to a target sequence, and a 3' terminal region that comprises a hairpin structure comprising a loop of single nucleotides bounded by a double stranded region of complementary nucleic acids, ending in a 3' terminal base complementary to a target sequence. In preferred embodiments, the double stranded hairpin region is at least 3 base pairs, at least 10 base pairs, at least 16 base pairs. The nucleic acid probes are incubated with a complex target population of nucleic acid strands (e.g., DNA, cDNA, gDNA, RNA, mRNA, tRNA, etc.), for example human genome DNA (gDNA) (e.g., whole or fragmented), under conditions that favor hybridization of complementary DNA strands such that nucleic acid sequences complementary to the single stranded portion of the 5' end of the nucleic acid probe and the probe 3 ' terminal base specifically hybridize to the probe. In some embodiments, the target nucleic acids are labeled on the 3' end with, for example, a detectable moiety (e.g., fluorophore, chromophore, radioisotope, etc.). In some embodiments, oligonucleotide probes comprising a central portion that is single stranded and complementary to a target sequence, and a 3' terminal region that comprises a hairpin structure comprising a loop of single nucleotides bounded by a double stranded region of complementary nucleic acids, ending in a 3' terminal base complementary to a target sequence find utility in hybridization assays for determining genetic anomalies such as deletions, translocations, and the like.
In some embodiments, oligonucleotide probes are synthesized and affixed to a substrate, for example a microarray slide or chip, as described in DNA Microarrays: A Molecular Cloning Manual, 2003, Eds. Bowtell and Sambrook, Cold Spring Harbor Laboratory Press, incorporated herein by reference in its entirety. In preferred embodiments, capture oligonucleotide probes are synthesized directly on a substrate, such as a microarray slide, using maskless array synthesizers (MAS), for example as described in US Patents and Patent Publications 7,157,229, 7,083,975, 6,444,175, 6,375,903, 6,315,958, 6,295,153, 5,143,854, 2007/0037274, 2007/0140906, 2004/0126757, 2004/0110212, 2004/0110211, 2003/0143550, 2003/0003032, and 2002/0041420, all of which are incorporated herein by reference in their entireties. When using a MAS instrument to print microarrays, the selection of oligonucleotide probe sequences are constructed in situ directly on the microarray slide under software control, such that individually customized arrays based on the particular needs of an investigator are created. Such arrays comprise hundreds, thousands, and millions of probes.
Oligonucleotide probes are typically synthesized from 3' to 5', whether synthesized in situ (e.g., MAS synthesis) on a substrate (e.g., microarray slide) or synthesized and then spotted onto a substrate. However, as most nucleic acid enzymes (e.g., restriction endonucleases, polymerases, terminal transferase, ligases, kinases, phosphatases, etc.) have activities from 5' to 3', enzymatic reactions require synthesis of probes using reverse chemistries (e.g., from 5' to 3'). As such, method and assay embodiments of the present invention comprise in situ synthesis of oligonucleotide probes synthesized preferentially from 5' to 3' using MAS instruments as described in, for example, Albert, T.J., et al., Nucl Acids Res 31(7) (2003) e35; incorporated herein by reference in its entirety).
The present invention provides methods and assays for detecting differences in nucleic acid sequences, for example single nucleotide polymorphisms, genomic copy number variants, methylation status, etc. In methods and assays of the present invention, target nucleic acids are hybridized with probes, wherein said probes are affixed (e.g., via in situ synthesis or otherwise) to a substrate or found in solution. In some embodiments, the probes are at least 15 nucleotides (nts) long, at least 20 nts, at least 25 nts, at least 30 nts, at least 35 nts, at least 40 nts, at least 45 nts, at least 50 nts, at least 55 nts, at least 60 nucleotides long. In some embodiments, probes of the present invention are synthesized in situ on a substrate, for example a microarray slide, microarray chip, bead, plate, etc. In preferred embodiments, the probes are synthesized in situ using MAS instrumentation wherein the 5' terminus of the probe is affixed to the substrate. In some embodiments, the probes are synthesized in solution and maintained in solution.
Probes of the present invention comprise a single stranded 5' end complementary to a target sequence, a 3' end that comprises a hairpin structure comprising a series of complementary bases that create a double stranded region and sequences that are not complementary that create a single stranded region amid the double stranded region (e.g., hairpin structure), and a 3' terminal base complementary to a specific target sequence. In some embodiments, the hairpin structure is at least 5 bases, 10 bases, at least 12 bases, at least 14 bases, at least 16 bases, at least 18 bases long. In some embodiments, the hairpin structure is preferably 16 bases. In some embodiments, the hairpin structure comprises SEQ ID NO: 1, as exemplified in Figure 3. However, the present invention is not limited by the sequence of the hairpin structure, and further examples of hairpin structures and their design are found in Varani, G., Ann Rev Biophys Biomol Struct 24 (1995) 379-404 and Antao, V.P., et al., Nucl Acids Res 19(21) (1991) 5901-5, both of which are incorporated herein by reference in their entireties. As exemplified in Figures 1 and 2, the nucleotide base on the probe that is complementary to the 3' terminal base of the probe hairpin determines assay specificity, and is sometimes referred to as the "allele specific base". As exemplified in Figure 10, the nucleotide base on the 5'- side or arm of the probe proximal to the hairpin structure also determines assay specificity. When the allele specific base is complementary to the corresponding base of the target strand, the hairpin and target molecules form a specific structure, termed the "invasive complex" that is recognized by FEN enzymes. When the base specific nucleotide is present in the target strand FEN cleaves the target strand on the 3' side of the base thereby releasing the non-hybridized, or flap, 5' end of the target strand. If the base is not complementary to the allele specific base, then the invasive complex does not form, and the target molecule is not cleaved by the FEN.
In some embodiments, after hybridization of the probe with the target nucleic acid, the probe/target complex is incubated with a cocktail comprising one or more of a flap endonuclease (FEN), ligase, Rec J, a ssDNA binding protein, and appropriate buffers and cofactors (ATP or NAD+) necessary for enzymatic reactions to occur. The FEN cleaves target molecules that form the invasive complex, resulting in a gap between the nucleic acid probe hairpin and the target nucleic acid molecule. It is contemplated that the inclusion of RecJ with or without a ssDNA binding protein increases the efficiency of the cleavase reaction thereby allowing for increased sensitivity in the cleaving of the invasive complexes. Ligase repairs the gap, covalently attaching the target molecule to the probe. If the invasive complex does not form, then the FEN does not cleave and the target molecule is not ligated to the probe. Unbound molecules are subsequently separated from the bound targets by washing. Since the target molecules are covalently attached to the probes on the substrate, washing can be performed with much higher stringency that those afforded to non-covalently bound hybridization methods, thereby increasing the removal of non-specifically bound, non-target molecules and greatly improving capture specificity and signal-to-noise ratios.
In some embodiments, target molecules that bind to the probe are identified by a detectable means (e.g. colorimetry, radiometry, fluorometry, gel electrophoresis, etc.) using data analysis instruments and software as described herein and as known to a skilled artisan.
As the target molecules are covalently bound to the probes, the arrays are capable of being washed with high stringency for removal of unbound, non-target molecules thereby allowing for increased reduction of background signal and increasing an assay's signal-to noise ratio. Applications of the present invention include, but are not limited to, comparative genomic hybridization (CGH), single nucleotide polymorphism genotyping, gene transcription profiling, genome methylation analysis, chromatin immunoprecipitation mapping, and the like.
In some embodiments, the present invention provides assays and methods for target capture of DNA for, for example, high throughput sequencing applications and other downstream applications.
In some embodiments, nucleic acid probes are in solution and bound at their 5' ends to a capturable moiety, for example a biotin moiety (Figure 2). The nucleic acid probes further comprise a 5' region that is single stranded and complementary to a target sequence and a 3' terminal region that comprises a hairpin structure comprising a loop of single nucleotides bounded by a double stranded region of complementary nucleic acids as previously described. In some embodiments, the hairpin structure is at least 5 bases, 10 bases, at least 12 bases, at least 14 bases, at least 16 bases, at least 18 bases long. In some embodiments, the probes are at least 15 nucleotides (nts) long, at least 20 nts, at least 25 nts, at least 30 nts, at least 35 nts, at least 40 nts, at least 45 nts, at least 50 nts, at least 55 nts, at least 60 nucleotides long. It is contemplated that the probe is preferably less than 100 bases. In some embodiments, the hairpin sequences comprise cleavable sequences for releasing the bound target sequences from the probe following ligation. For example, the hairpin sequences comprise a restriction endonuclease (RE) site or one or more uracils. The nucleic acid probes are incubated with a complex target population of nucleic acid strands (e.g., DNA, cDNA, gDNA, RNA, mRNA, tRNA, etc.), for example fragmented human genome DNA (gDNA), under conditions that favor hybridization of complementary DNA strands such that fragments of the genome complementary to the single stranded portion of the 5' end of the nucleic acid probe specifically hybridize to the probe. In some embodiments, the target nucleic acids are labeled on the 3 ' end with, for example, a detectable moiety (e.g., fluorophore, chromophore, radioisotope, etc.).
When the allele specific base is complementary to the corresponding base of the target strand, as seen in Figure 2, the hairpin and target molecules hybridize and form a specific structure that is recognized by FEN enzymes. When the base specific nucleotide is present in the target strand (Figure 2) FEN cleaves the target strand on the 3' side of the base thereby releasing the non-hybridized, or flap, 5' end of the target strand. If the base is not complementary to the allele specific base, then the invasive complex does not form, and the target molecule is not cleaved by the FEN. It is contemplated that the incorporation of RecJ with or without a ssDNA binding protein in conjunction with a FEN will increase the efficiency of the cleavase enzyme.
In some embodiments, following hybridization, the probe complex is incubated with a cocktail comprising one or more of a FEN enzyme, ligase enzyme, RecJ, a ssDNA binding protein, appropriate buffers and cofactors (ATP or NAD+) necessary for the required enzymatic reactions to occur. The FEN cleaves target molecules that form the invasive complex, resulting in a gap between the nucleic acid probe hairpin and the target nucleic acid molecule. As previously described, the ligase repairs the gap by covalently attaching the target molecule to the probe. If the invasive complex does not form, then the FEN does not cleave and the target molecule is not ligated to the probe, hi some embodiments, as exemplified in Figure 2B, the target molecules that are covalently attached to a labeled probe in solution, in this instance a biotin labeled probe, are captured (e.g., bound) by streptavidin (SA) coated beads, wherein streptavidin binds the biotin of the labeled probe as known to those skilled in the art. Following streptavidin binding, the beads are removed from solution and washed thereby removing unbound, untargeted molecules from the bound target molecules on the captured beads and purifying the target molecule/probe complexes away from unwanted reaction components. Since the target molecules are covalently attached to the SA bound biotin labeled probe, washing can be performed with much higher stringency that those afforded to non-covalently bound hybridization methods, thereby increasing the removal of non-specifically bound, non-target molecules and greatly improving capture specificity and signal-to-noise ratios.
In some embodiments, the target molecules are released from the SA bound probe by exposing the beads comprising the target molecules to a restriction endonuclease, for example when the recognition site of the RE is incorporated into the hairpin sequence of the probe during synthesis. In some embodiments, if one or more uracils are incorporated into the hairpin during synthesis, the target molecules are released from the SA bound probes by incubation with uracil-DNA-glycosylase (UDG) followed by Endonuclease VIII digestion at the damaged site. The present invention is not limited to the method of release of the target molecule from the bound probe and other methods know in the art to cleave DNA are contemplated for use with methods and assays of the present invention.
Once liberated, the targeted molecules are applied to downstream applications, such as sequencing using, for example, a high-throughput sequencer. Methods and assays of the present invention further provide an investigator the ability to precisely define the end point and directionality of each captured target nucleic acid molecule and, as a consequence, each sequencing read. It is contemplated that release of the target sequence using enzymatic means as described herein is amenable to release of target sequences from probes wherein said probes are synthesized on a solid support, such as a microarray slide, as described herein.
In some embodiments, methods and assays of the present invention provide for analysis of single nucleotide polymorphisms (SNPs). hi some embodiments, the present invention provides methods and assays for analysis of copy number variation (CNV) in DNA samples, for example genomic DNA samples. SNP and CNV analysis is useful in association studies, for example between different species and between SNPs and CNVs associated with diseases and disorders. As such, methods and assays of the present invention provide for the analysis of genomic variation and their association with diseases in a particular subject, for example a human subject. However, it is contemplated that the present invention is not limited to analysis of genomic sequences from any particular genus and/or species, for example any prokaryotic or eukaryotic sequence is considered amenable to applications of the present invention, for research, diagnostic or therapeutic use. In some embodiments, the present invention is not limited to a particular set of hybridization conditions. However, stringent hybridization conditions as known to those skilled in the art are preferably employed. Hybridization solutions of use with the present invention include, but are not limited to, those found in NimbleGen Hybridization Kits (Roche NimbleGen, Madison WI). In some embodiments, the present invention provides washing the probe/target complexes following enzymatic cleavage and ligation reactions thereby removing unbound and non- specifically bound nucleic acid molecules. In some embodiments, the present invention provides washes of differential stringency, for example a wash buffer I comprising 0.2x SSC, 0.2 % (v/v) SDS, and O.lmM DTT, a wash buffer II comprising 0.2x SSC and O.lmM DTT and a wash buffer III comprising 0.5x SSC and O.lmM DTT. In some embodiments, solutions and buffers for washing, hybridization, and enzymatic reactions comprise lithium. The present invention is not limited by composition of the hybridization and/or wash buffers. In some embodiments, the target sequences are eluted from the probes following, for example RE digestion, using, for example, water or similar low solute solutions known to those skilled in the art.
In some embodiments, the present invention provides capture of target nucleic acid sequences for subsequent use in targeted array-based-, shotgun-, capillary-, or other sequencing methods known to the art. As known to a skilled artisan, sequencing by synthesis is understood to be a sequencing method which monitors the generation of side products upon incorporation of a specific deoxynucleoside-triphosphate during the sequencing reaction (Ronaghi, M., et al., Science 281 (1998) 363-65; incorporated herein by reference in its entirety). For example, one or the more prominent embodiments of the sequencing by synthesis reaction is the pyrophosphate sequencing method. In pyrosequencing, generation of pyrophosphate during nucleotide incorporation is monitored by an enzymatic cascade which results in the generation of a chemo-luminescent signal. The 454 Genome Sequencer System (Roche Applied Science cat. No. 04760085001) is based on the pyrophosphate sequencing technology. For sequencing on a 454 GS20 or 454 FLX instrument, the average genomic DNA fragment size is preferably in the range of 200 or 600 bp, respectively. Sequencing by synthesis reactions can also comprise a terminator dye type sequencing reaction. In this case, the incorporated dNTP building blocks comprise a detectable label, such as a fluorescent label, that prevents further extension of the nascent DNA strand. The label is removed and detected upon incorporation of the dNTP building block into the template/primer extension hybrid, for example, by using a DNA polymerase comprising a 3' -5' exonuclease or proofreading activity. However, the present invention is not limited by the type of downstream application that may used in conjunction with the present invention.
In some embodiments, the target sequences are released from the oligonucleotide probe by enzymatic digest (e.g., restriction endonuclease, UDG and Endo VIII, etc.) and eluted away from the probe and sequenced. In some embodiments, the sequencing is performed using a 454 Life Sciences Corporation sequencer. In some embodiments, the present invention provides target sequence amplification following elution by emulsion PCR (emPCR) following manufacturer's protocols. The beads comprising the clonally amplified target nucleic acids from the emPCR are transferred into a picotiter plate according to the manufacturer's protocol and subjected to a pyrophosphate sequencing reaction for sequence determination.
In some embodiments, the present invention provides methods and assays wherein a plurality of different target sequences is contemplated for detection on one array or in one solution, for example for concurrent capture and detection of multiple target sequences. In such embodiments, a two color labeling is contemplated (e.g., two channel fluorescence, fluorescent/non-fluorescent, etc.). For example, one target sequence is labeled with one detectable moiety and another target sequence is labeled with a second detectable moiety. For example, one target sequence is labeled with a fluorescent moiety (e.g., fluorescein, Cy-3, Cy-5, etc.) and the second target sequence is labeled with a non-fluorescent moiety (e.g., biotin, digoxygenin) or a fluorescent moiety differing in wavelength detection from the first fluorescent moiety. Terminal transferase can be used to 3' end label the target sequences by using, for example, ddCTP conjugates of the fluorophore (e.g., fluorescein- 12-ddCTP) and the second moiety (e.g., biotin- 11-ddCTP). As such, dual channel detection or differential moiety detection allows for differentiation between two different captured target sequences.
In some embodiments, the signal detected upon completion when practicing methods and assays of the present invention as described herein are further amplified. Examples of signal amplification methods include, but are not limited to, those found in Tyramide Signal Amplification kits commercially available through, for example NEN® Life Sciences Products, Inc. (Boston MA). In some embodiments, data analysis is performed on the bound target sequences. Data analysis is performed, for example, to identify a SNP or CNV as found in a captured target sequence. Data analysis is performed using any array scanner, for example an Axon GenePix 4000B fluorescent scanner. Once data is captured by the scanner, bioinformatics programs are utilized to analyze the captured data. Bioinformatics programs useful in data analysis from fluorescent microarray formats include, but are not limited to SignalMap™ (NimbleGen) and NimbleScan™ (NimbleGen) however any scanner and bioinformatics programs capable of capturing and analyzing data generated by the methods of the present invention are equally amenable. Data output is visualized on, for example, any computer screen or other device capable of displaying data generated when practicing the present invention.
In some embodiments, the present invention provides kits for practicing methods and assays as described herein. In some embodiments, the kits comprise reagents and/or other components (e.g., buffers, instructions, solid surfaces, containers, software, etc.) sufficient for, necessary for, performing target nucleic acid capture of target nucleic acid molecules as herein described. Kits are provided to a user in one or more containers (further comprising one or more tubes, packages, etc.) that may require differential storage, for example differential storage of kit components/reagents due to light, temperature, etc. requirements particular to each kit component/reagent. In some embodiments, a kit comprises one or more solid supports, wherein said solid support is a microarray slide or a plurality of beads, upon which are affixed a plurality of oligonucleotide capture probes. In some embodiments, a kit comprises oligonucleotide probes in solution, wherein said probes comprise a capture moiety, and beads, wherein said beads are designed to bind to the capture moiety as affixed to the oligonucleotide probe. For example, such a moiety is a biotin label which can be used for immobilization on a streptavidin coated solid support. Alternatively, such a modification is a hapten like digoxygenin, which can be used for immobilization on a solid support coated with a hapten recognizing antibody.
In some embodiments, the kit of the present invention comprises at least one or more compounds and reagents for performing enzymatic reactions, for example one or more of a flap endonuclease, a DNA ligase, a RecJ exonuclease, a ssDNA binding protein, a T4 polynucleotide kinase, a restriction endonuclease, a DNA polymerase, a terminal transferase, Kl enow, etc. In some embodiments, a kit comprises one or more of hybridization solutions, wash solutions, and/or elution reagents. Examples of wash solutions found in a kit include, but are not limited to, Wash Buffer I (0.2x SSC, 0.2 % (v/v) SDS, 0.ImM DTT), and/or Wash Buffer II (0.2x SSC, 0.ImM DTT) and/or Wash Buffer III (0.5x SSC, O.lmM DTT). In some embodiments, one or more buffers or solutions as found in the kit comprise lithium. In some embodiments, a kit comprises one or more elution solutions, wherein said elution solutions comprise purified water and/or a solution containing TRIS buffer and/or EDTA, or other low solute solution.
The following examples are provided in order to demonstrate and further illustrate certain embodiments and aspects of the present invention and are not to be construed as limiting the scope thereof.
Example 1
Target capture of creatine phosphokiπase 6 (CPK6) and restriction fragmented PCR Amplicons
Experiments were designed to test for ligation efficiencies in methods and assays of the present invention. Experiments were designed utilizing 3' labeled CPK6 oligonucleotides (Integrated DNA Technologies (IDT), Coralville IA) and PCR fragments amplified from E. coli genomic DNA (ATCC No. 700926D-5) yielding amplicons from around 1100 to around 1500 bps (SEQ ID NO: 2, 3 and 4).
Oligonucleotide probes of 50 and 60 mers were designed that comprised a 16 bp hairpin. The hairpin sequence used was 5'-CCGGAGGATACTCCGG-3' (SEQ ID
NO: 1), as shown in Figure 3. Control probes were synthesized that did not contain hairpin structures. A quartet of probes was designed representing all four bases per strand, as such eight total probes were designed (e.g., 4 for each strand of the DNA target) for the target nucleotide within the query sequence. Each quartet per strand contained the same probe sequence except the terminal base on the 3 ' end of the
50/60 mer probe. Probes were synthesized in situ at Roche NimbleGen (Madison,
WI) on an array with a density of 2.1 million probes per array (HD2).
Three PCR fragments were amplified from genomic E. coli DNA using PCR primers;
1277-F 5'-ATGAGCAACAATGAATTCCA-S ' (SEQ ID NO: 5)
1277-R 5'ATGGTCAGCGGATACAGGAA-S' (SEQ ID NO: 6)
2205-F 5ΑTGAATGACACCAGCTTCGA-3' (SEQ ID NO: 7) 2205-R 5'GCCAGTAGCGTAATCGGATG-S' (SEQ ID NO: 8)
2825-F 5'-ATGTCTGAACAACACGCACA-S ' (SEQ ID NO: 9)
2825-R 5 'AC AGAAT AACGTCGCGGATG-3'. (SEQ ID NO: 10)
PCR amplification conditions included initial denaturation at 94 0C for 2 min followed by 30 cycles of 94 °C/30 seconds, 55 °C/60 seconds, 72 0C 60, with a final elongation of 72 °C for 7 minutes. The fragments were digested with two restriction enzymes (Hhal and NIaIII) yielding fragments of various sizes with 3 ' overhangs. The restriction fragmented amplicons were pooled in equimolar concentrations and further treated with antarctic phosphatase (NEB) to dephosphorylate 5' end. This prevents self-self ligation and direct non-specific ligation to the probes synthesized on the array. Fragmented and dephosphorylated amplicons were labeled with Cy3-ddCTP on their 3' ends with terminal transferase (TdT, Roche) and precipitated away from non-labeled fragments using methods known to those skilled in the art, for example as found in Molecular Cloning, A Laboratory Manual, Eds. Sambrook et al., Cold Spring Harbor Press (incorporated herein by reference in its entirety). Labeled fragments were combined with phosphorylated CPK6 oligonucleotides that were labeled on the 3' end with Cy3 (IDT).
The microarray slides were sealed with NimbleChip HX3 mixers (Roche NimbleGen, Madison WI). Denatured and labeled target amplicons were applied to a microarray. Probes found on the microarray included those with and without a hairpin. The microarray slides with target sequences were allowed to hybridize overnight at 42 °C in a MAUI Hybridization System (BioMicro) under stringent conditions, washed three times with wash buffer and scanned. Ligation was performed using Ampligase® (Epicentre, Madison WI) in appropriate buffer and incubation was carried out at 45 °C for 4 hours. The slides were washed three times and the arrays boiled in water with constant stirring for approximately 2 minutes.
After boiling, the microarray slides were washed and scanned. Scanning was performed using an Axon GenePix 4000B fluorescent scanner. Data captured for each scan and data analysis was performed using SignalMap™ (NimbleGen) and
NimbleScan™ (NimbleGen) software applications.
Results demonstrate that for probes with no hairpins (CPK6 control) there was no target capture (Figure 4). However, when the probe comprised a hairpin and the target fragment sequence comprised the complementary target base, the ligase ligated the target sequence to the probe. The target sequence capture was specific to the identity of the terminal base at the 5' end of each restriction fragment, such that for each quartet of probes representing a query base for a partial fragment of sequence, only one of the four probes has a ligated labeled fragment. This results in high signal intensity for the correct ligation probe in comparison to the background intensity of the remaining three bases in the quartet per strand. The signal intensities associated with the probe with the correct base perfectly identified the sequence based prediction for locations of restriction sites for Hhal and NIaIII.
Example 2 Target Capture of Creatine phosphokinase 6 (CPK6) and PCR Amplicons
Experiments were designed to test for flap endonuclease and ligation efficiencies in methods and assays of the present invention. Experiments were designed utilizing a 3' labeled CPK6 oligonucleotides (IDT) and PCR fragments amplified from E. coli genomic DNA as described in Example 1. Oligonucleotide probes of 50 and 60 mers were designed that comprised a 16 bp hairpin and a complementary base on the terminal 3' end. The hairpin sequence used was 5 'CCGG AGGAT ACTCCGG3' (SEQ ID NO: 1). Control probes were synthesized that did not comprise hairpin structures. A quartet of probes was designed, as exemplified in Figure IA, representing all four bases per strand, as such eight total probes were designed (e.g., 4 for each strand of the DNA target) for the target nucleotide within the query sequence. Probes were synthesized in situ at Roche NimbleGen (Madison, WI) on an array with a density of 2.1 million probes per array (HD2).
Three PCR fragments were amplified from genomic E. coli DNA using PCR primers and conditions as previously described. The fragments were digested with two restriction enzymes (Hhal and NIaIII) yielding fragments of various sizes with 3' overhangs. The restriction fragmented amplicons were pooled in equimolar concentrations and further treated with antarctic phosphatase (NEB) to dephosphorylate 5' end. This prevents self-self ligation and direct non-specific ligation to the probes synthesized on the array. Fragmented and dephosphorylated amplicons were labeled with Cy3-ddCTP on their 3' ends with terminal transferase (TdT, Roche) and precipitated away from non-labeled fragments using methods known to those skilled in the art, for example as found in Molecular Cloning, A Laboratory Manual, Eds. Sambrook et al., Cold Spring Harbor Press (incorporated herein by reference in its entirety). Labeled fragments were combined with dephosphorylated CPK6 oligonucletides that were labeled on the 3' end with Cy3 (IDT).
The microarray slides were sealed with NimbleChip HX3 mixers (Roche NimbleGen, Madison WI) and denatured, labeled target amplicons were applied to a microarray. Probes found on the microarray included those with and without a hairpin. The microarrays slides with target sequences were allowed to hybridize overnight at 42 °C in a MAUI Hybridization System (BioMicro) under stringent conditions, washed three times with wash buffer and scanned. Cleavase enzyme in appropriate buffer (10 raM MOPs: pH 7.5, 100 mM LiCl, 4 mM MgC12 ) was added to the microarray slides with the bound target sequences and the reactions were incubated at 45 °C for 1 hour, washed three times with wash buffer and scanned. Ligation was performed using Ampligase® (Epicentre, Madison WI) in appropriate buffer and incubation was carried out at 45 °C for 4 hours. The slides were washed three times and the arrays boiled in water with constant stirring for approximately 2 minutes. After boiling, the microarray slides were washed and scanned. Scanning was performed using an Axon GenePix 4000B fluorescent scanner. Data captured for each scan and data analysis was performed using SignalMap™ (NimbleGen) and NimbleScan™ (NimbleGen) software applications.
Results demonstrate that for probes with no hairpins (CPK6 control), there was no target capture. However, when the probe comprised a hairpin with a complementary base to the target sequence, and the target sequence comprised the target base, the FEN and ligase enzymes cleaved the target sequence and ligated the target to the probe (respectively). The target sequence capture was specific to the identity of the complement base such that for a quartet of probes representing a query base for a partial fragment of sequence, only one of the four probes had a ligated labeled fragment after cleavase reaction. This results in high signal intensity for the correct base call in comparison to the background intensity of the remaining three bases in the quartet per strand (Figure 5). The fold differences between correct and incorrect base within the quartet were calculated as the ratio between the signal intensity of the correct base call by the average of three incorrect bases.
Fold changes of up to 35 fold were detected across probes that were synthesized on the array to query all fragments of the PCR amplicon, as demonstrated in Figure 5. Example 3
Target Capture of Creatine phosphokinase 6 (CPK6) and randomly fragmented genomic DNA
Experiments were designed utilizing human and E. coli genomic DNA (gDNA). Oligonucleotide probes were designed as described in Example 1 , such that probes were synthesized in situ at Roche NimbleGen (Madison, WI) at a density of 2.1 million probes per array (HD2). Genomic DNA (gDNA) was fragmented either with sonication or randomly amplified using Klenow fragment with random primers of various lengths (9 mers, 10 mers, 12 mers, and 15 mers) yielding amplified target sequences of differential lengths. The fragments were treated with antarctic phosphatase and labeled with Cy3-ddCTP on their 3' ends using terminal transferase (TdT) and precipitated away from non-labeled fragments using methods known to those skilled in the art. The microarray slides were sealed with HX3 mixers (NimbleGen Roche) and denatured, labeled target sequences were applied to a microarray (5-30 μg sample/subarray). Probes found on the microarray included those with and without a complement base immediately after the hairpin on their 3' ends, as well as probes with no hairpins. The microarray slides with target sequences were allowed to hybridize overnight at 42 °C, washed three times with wash buffer and scanned. Cleavase enzyme in appropriate buffer was added to the microarray slides with the bound target sequences and the reactions were incubated at 42 °C for 1-2 hours, washed three times with wash buffer and scanned. Ligation was performed using Ampligase® (Epicentre, Madison WI) in appropriate buffer and incubation carried out at 45 °C for 4 hours. The slides were washed three times and the arrays boiled in water with constant stirring for approximately 2 minutes. After boiling, the microarray slides were washed and scanned using an Axon GenePix 4000B fluorescent scanner. Data captured by the scanner and data analysis was performed using SignalMap™ (Roche NimbleGen, Inc.) and NimbleScan™ (Roche NimbleGen, Inc.) software applications.
Results demonstrated that for probes with no hairpins (control), there was no target capture. However, when the probe comprised a hairpin with a complementary base, and the target sequence comprised the target base, the FEN and ligase enzymes provided assay specificity in identifying target captured sequences as determined by fluorescence detection methodologies. Example 4
Evaluation of cleavases with increasing ssDNA flap length
Twenty cleavase enzymes were evaluated for efficacy in the cleavase reactions; arbitrarily named C1-C5, P1-P3 and F1-F12. The cleavase enzymes were furnished by Third Wave Technologies (Madison, WI 53719). Ampligase® (Epicentre, Madison WI). Two microarray slides, each containing 12 identical subarrays were utilized for each experiment to cover all of the 20 cleavases assayed, the probes of which were synthesized by MAS using reverse chemistry (synthesis 5 '-3' where the 5' end of probe was proximal to the substrate) and each of the 12 subarrays contained approximately 120,0000 probes. The probes were designed to represent three different PCR fragments, sense and antisense strand for each of the three fragments. Each probe was designed with sequence specificity correlating to the target amplicon sequences and a 16 bp hairpin (sequence of 5'- CCGGAGGAT ACTCCGG-3' (SEQ ID NO: 1 as seen in Figure 3) with a 3' overhang representing an A, C T or G for both the sense and antisense strand (therefore, 8 probes per PCR fragment) for the target nucleotide within the query sequence. Control probes were synthesized that did not comprise hairpin structures.
Three different fragments of E. coli were amplified, yielding 1277, 2205 and 2825 bp amplicons. Each amplicon was further fragmented by restriction digest; the 1277bp and 2825bp amplicons were digested with NIaIII and the 2205bp amplicon was digested with Mbol yielding digested fragments of various lengths (Figure 6). The fragments were treated with antarctic phosphatase (NEB) to dephosphorylate 5' end. This prevents self-self ligation and direct non-specific ligation to the probes synthesized on the array. Fragmented and dephosphorylated amplicons were labeled with Cy3-ddCTP on their 3' ends with terminal transferase (TdT, Roche) and precipitated away from non-labeled fragments using methods known to those skilled in the art, for example as found in Molecular Cloning, A Laboratory Manual, Eds. Sambrook et al., Cold Spring Harbor Press (incorporated herein by reference in its entirety).
Labeled target nucleic acids were denatured and applied to the subarray on the microarray slides. The microarrays slides with target sequences were allowed to hybridize overnight at 42 0C in a MAUI Hybridization System (BioMicro) under stringent conditions, washed three times with wash buffer and scanned. One of the 20 experimental cleavase enzymes and Ampligase ® in cleavase buffer (final concentration of 10 mM MOPs: pH 7.4, 100 mM LiCl, 4 mM MgC12, IX NAD) and was added to each of the subarrays on the microarray slides with the bound target sequences and the reactions were incubated at 45 0C for 2 hours, washed three times with wash buffer and scanned. Another round of Ampligase®, this time in its appropriate buffer, was added to each subarray and incubation was carried out at 45 0C for an additional 4 hours. The slides were washed three times and the arrays boiled in water with constant stirring for approximately 2 minutes. After boiling, the microarray slides were again washed and scanned. Scanning was performed using an Axon GenePix 4000B fluorescent scanner. Data captured for each scan and data analysis was performed using SignalMap™ (Roche NimbleGen, Inc.) and NimbleScan™ (Roche NimbleGen, Inc.) software applications.
Figure 7 demonstrates the efficacy of the cleavase/ligase combination in determining genetic sequence of, in this case, a PCR fragment wherein the target sequence had a "C" in the interrogation position. Upon overnight hybridization, there was no discrimination among the bound targets for the probe sequence, whereas incorporation of cleavase and ligase dramatically increased the discrimination resulting in correct base calling at that location. Further, Figure 8 demonstrates that as the length of the 5' end of the bound target fragment increases (e.g., flap length increases), an increase in incorrect base calling occurs. Base calling, or discrimination at a single nucleotide, can be determined by the calculation:
( Signal IntensitySecondBπghtestProbe ")
D =
{ Signal IntensityBπghtestProbe J
A low discrimination score denotes increased confidence for a correct base call and typically as the flap length increases so does the discrimination score, as such so does the incidence of incorrect base calling. Figure 8 demonstrates this phenomenon as exemplified with twelve of the difference cleavase molecules evaluated using 50bp flap length as point of reference and <0.5D score as correct base calling.
Example 5
Evaluation of the effect of RecJ on cleavase activity
Three PCR fragments as described in Example 4 were utilized to evaluate the ability of RecJ to increase the activity of cleavases for digesting longer 5' target flap ends. Experimental parameters as found in Example 4 were followed with the following exception. After the overnight hybridization and stringency washes, approximately 120 Units of RecJf (New England Biolabs, Ipswitch MA; a recombinant fusion protein of Red and a maltose binding protein (MBP) which retains the same enzymatic properties as wild-type RecJ (MBP added to enhance RecJ solubility)) in RecJ buffer was added to the arrays followed by incubation at 37 °C for 1 hour. Addition of a cleavase and thermostable ligase were as previously described. Arrays were analyzed as previously described.
The addition of RecJ in conjunction with a cleavase enzyme greatly increased the activity of the cleavase. As seen in Figure 9B, treatment of the hybridized complexes with cleavase in conjunction with RecJ increased the activity of the cleavase as compared to treatment with cleavase without RecJ (Figure 9A). Without RecJ as the flap length increased the incidence of incorrect base calling increased as previously demonstrated, such that a flap length of greater than approximately 45 bp led to an increased D score. Conversely, in the presence of RecJ the cleavase activity was maintained due to the activity of RecJ on the target flap overhang, with resultant D scores of around 0.5 or lower resulting in an increase in correct base calls. As such, the inclusion of RecJ in conjunction with a cleavase greatly improves the incidence of correct base calling in a target sample regardless of the length of the target flap overhang.
Example 6
Positioning of the interrogation nucleotide on the 5 '-side of the probe
Experiments were performed to evaluate the consequences of repositioning the interrogation nucleotide on the probe and its effect on correct base calling for genomic mutation detection. Instead of positioning the interrogation nucleotide after the hairpin structure and at the 3 ' end of the probe (as exemplified in Figures 1, 2A and 3), the interrogation nucleotide was instead placed immediately prior to the hairpin structure on the 5' side (or 5 'arm) (Figure 10) and the 3' end of the probe was designed to be complementary to the known target sequence. It was contemplated that by positioning the interrogation nucleotide adjacent to the hairpin structure, a dual specificity with respect to both the cleavase and the ligase enzymes is achieved as compared to just the cleavase lending specificity to the detection of mutations, including SNPs. By positioning the interrogation nucleotide as described, the cleavase lends specificity as its activity for detecting and cleaving tripartite structures and the ligase will ligate those cleaved products where the interrogation nucleotide is hybridized to its complement. As such, it is contemplated that a dual specificity is provided resulting in a decrease in false positive base calling of a sample. Figure 10 illustrates a comparison of hairpin configuration for single vs. dual enzymatic specificity in cleavase and ligase reactions. Hairpin configuration has an oligomer probe synthesized from 5'-3' with a hairpin of stem-length (e.g., 6 bp - 12 bp) with a 1 bp overhang on the 3' end (Figure 1OA, C). For each query base, 4 probes are synthesized with hairpins with a single base pair overhang, each representing A, C, T and G. The 3' end of the probe sequence also complements the overhang on the 3' end of the hairpin. Hairpin configuration in Figure 1OB, D has an oligomer probe synthesized from 5'-3' with a hairpin of stem-length (e.g., 6 bp - 12 bp). For each query base, 4 probes are synthesized where the last base pair of the hairpin sequence is designed such that it is complementary to the (query base +1) of a known target sequence. For each query base, all four probes have an identical hairpin sequence, but differ in the terminal 3 ' end base of the oligomer probes and are synthesized to represent A, C, T and G before synthesis of the hairpin. These generate base-specific substrates for ligation between the 3' end of the hairpin and the 5' end of the cleaved target. In the illustrated embodiments shown in Figure 10, the interrogation nucleotide is positioned immediately prior to the hairpin structure on the 5 '-side or arm of the probe. In some embodiments, the proximal nucleotide is about 2, 3, 4, 5, 6, 7, 8, 9, or 10 bases upstream of the double stranded hairpin structure on the 5' side.
All publications and patents mentioned in the present application are herein incorporated by reference. Various modification and variation of the described methods and compositions of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention that are obvious to those skilled in the relevant fields are intended to be within the scope of the following claims.

Claims

Patent Claims
1. A method for capturing target nucleic acid sequences comprising:
a) providing: i) a nucleic acid sample wherein said nucleic acid sample may or may not comprise a target sequence, ii) at least one flap endonuclease and at least one ligase, and iii) a plurality of oligonucleotide probes, wherein said probes comprise target sequences and a hairpin structure, b) applying said nucleic acid sample to said oligonucleotide probes under conditions wherein hybridization is allowed to occur between target sequences and probes; and c) applying at least one flap endonuclease and at least one ligase to the hybridized nucleic acid/probes complex under conditions wherein enzymatic reactions are allowed to occur thereby capturing a nucleic acid target sequence.
2. The method of claim 1 , wherein said nucleic acid sample further comprises a detection moiety.
3. The method of claim 2, wherein said detection moiety comprises a fluorescent moiety.
4. The method of claim 3, wherein said fluorescent detection moiety is Cy3.
5. The method of claim 2, wherein said detection moiety is detected using a fluorescent scanner.
6. The method of claim 5, further comprising data analysis of the detected target nucleic acids.
7. The method of claim 1, wherein said nucleic acid sample comprises genomic DNA or a derivative thereof.
8. The method of claim 1, wherein said nucleic acid sample is from a mammal.
9. The method of claim 1 , wherein said nucleic acid sample is from a human.
10. The method of claim 1, wherein at least one of said target sequences comprises a single nucleotide polymorphism.
11. The method of claim 1, wherein at least one of said target sequences comprises a genomic copy number variant.
12. The method of claim 1, wherein said hairpin structure comprises SEQ ID NO: 1.
13. The method of claim 1 , wherein said ligase is a thermostable ligase.
14. The method of claim 1, wherein said probes are affixed to a substrate.
15. The method of claim 14, wherein said substrate is a microarray slide.
16. The method of claim 1, wherein the plurality of oligonucleotide probes comprises an interrogation nucleotide.
17. The method of claim 16, wherein the interrogation nucleotide is positioned at the terminal 3 'end of the probe.
18. The method of claim 16, wherein the interrogation nucleotide is positioned proximal to the hairpin structure on the 5 '- side of the probe.
19. The method of claim 16, wherein the interrogation nucleotide is positioned about 2, 3, 4, 5, 6, 7, 8, 9, or 10 bases upstream of the hairpin structure on the 5'- side of the probe.
20. The method of claim 1 further comprising providing a component selected from the group consisting of RecJ and a single strand binding protein.
21. The method of claim 1 , wherein the probes provide dual specificity.
22. A method for capturing target nucleic acids comprising:
a) providing: i) a nucleic acid sample wherein said nucleic acid sample comprises a detection moiety and may or may not comprise a target sequence and , ii) at least one flap endonuclease, at least one ligase, and iii) a plurality of oligonucleotide probes, wherein said probes comprise target sequences and a hairpin structure wherein said hairpin structure comprises at least one cleavable sequence, b) applying said nucleic acid sample to said oligonucleotide probes under conditions wherein hybridization is allowed to occur between target sequences and probes, c) applying at least one flap endonuclease and at least one ligase to the hybridized nucleic acid/probes complex under conditions wherein enzymatic reactions are allowed to occur thereby capturing a nucleic acid target sequence.
23. The method of claim 22, wherein said at least one cleavable sequence comprises a restriction endonuclease site.
24. The method of claim 22, further comprising releasing of the nucleic acid target sequences from the probes by digestion with a restriction endonuclease.
25. The method of claim 24, further comprising detecting said released target nucleic acid sequences by sequencing.
26. A composition for sequence specific nucleic acid capture comprising a flap endonuclease, a ligase, and an oligonucleotide probe wherein said probe comprises a hairpin structure and a complementary target nucleic acid sequence.
27. A kit for capturing and detecting nucleic acid sequences comprising:
a) at least one flap endonuclease, b) at least one thermostable ligase, c) a plurality of oligonucleotide probes affixed to a substrate, and d) at least one buffer.
28. The kit of claim 27 further comprising a component selected from the group consisting of RecJ and a single strand binding protein.
PCT/EP2009/002318 2008-04-01 2009-03-31 Methods and assays for capture of nucleic acids WO2009121550A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2011502277A JP2011516050A (en) 2008-04-01 2009-03-31 Methods and assays for capture of nucleic acids
CN2009801199768A CN102046811A (en) 2008-04-01 2009-03-31 Methods and assays for capture of nucleic acids
CA2725405A CA2725405A1 (en) 2008-04-01 2009-03-31 Methods and assays for capture of nucleic acids
EP09727453A EP2262909A1 (en) 2008-04-01 2009-03-31 Methods and assays for capture of nucleic acids

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4129008P 2008-04-01 2008-04-01
US61/041,290 2008-04-01

Publications (1)

Publication Number Publication Date
WO2009121550A1 true WO2009121550A1 (en) 2009-10-08

Family

ID=40718733

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/002318 WO2009121550A1 (en) 2008-04-01 2009-03-31 Methods and assays for capture of nucleic acids

Country Status (6)

Country Link
US (1) US20090246788A1 (en)
EP (1) EP2262909A1 (en)
JP (1) JP2011516050A (en)
CN (1) CN102046811A (en)
CA (1) CA2725405A1 (en)
WO (1) WO2009121550A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10557851B2 (en) 2012-03-27 2020-02-11 Ventana Medical Systems, Inc. Signaling conjugates and methods of use
EP3759243B1 (en) * 2018-02-28 2023-09-27 Synpromics Ltd. Methods and compositions for enriching nucleic acids

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
EP1984738A2 (en) 2006-01-11 2008-10-29 Raindance Technologies, Inc. Microfluidic devices and methods of use in the formation and control of nanoreactors
EP2481815B1 (en) 2006-05-11 2016-01-27 Raindance Technologies, Inc. Microfluidic devices
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
EP3536396B1 (en) 2006-08-07 2022-03-30 The President and Fellows of Harvard College Fluorocarbon emulsion stabilizing surfactants
US8772046B2 (en) 2007-02-06 2014-07-08 Brandeis University Manipulation of fluids and reactions in microfluidic systems
US8592221B2 (en) 2007-04-19 2013-11-26 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
US12038438B2 (en) 2008-07-18 2024-07-16 Bio-Rad Laboratories, Inc. Enzyme quantification
EP4047367A1 (en) 2008-07-18 2022-08-24 Bio-Rad Laboratories, Inc. Method for detecting target analytes with droplet libraries
US8528589B2 (en) 2009-03-23 2013-09-10 Raindance Technologies, Inc. Manipulation of microfluidic droplets
US20100323914A1 (en) * 2009-06-23 2010-12-23 Affymetrix, Inc. Enzymatic Methods for Genotyping on Arrays
WO2011042564A1 (en) 2009-10-09 2011-04-14 Universite De Strasbourg Labelled silica-based nanomaterial with enhanced properties and uses thereof
WO2011079176A2 (en) 2009-12-23 2011-06-30 Raindance Technologies, Inc. Microfluidic systems and methods for reducing the exchange of molecules between droplets
WO2011100604A2 (en) 2010-02-12 2011-08-18 Raindance Technologies, Inc. Digital analyte analysis
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
US9194838B2 (en) 2010-03-03 2015-11-24 Osaka University Method and device for identifying nucleotide, and method and device for determining nucleotide sequence of polynucleotide
WO2012045012A2 (en) 2010-09-30 2012-04-05 Raindance Technologies, Inc. Sandwich assays in droplets
WO2012109600A2 (en) 2011-02-11 2012-08-16 Raindance Technologies, Inc. Methods for forming mixed droplets
WO2012112804A1 (en) 2011-02-18 2012-08-23 Raindance Technoligies, Inc. Compositions and methods for molecular labeling
GB201107863D0 (en) * 2011-05-11 2011-06-22 Olink Ab Method and product
EP3709018A1 (en) 2011-06-02 2020-09-16 Bio-Rad Laboratories, Inc. Microfluidic apparatus for identifying components of a chemical reaction
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
WO2013003630A2 (en) * 2011-06-28 2013-01-03 Igor Kutyavin Methods and compositions for enrichment of nucleic acids in mixtures of highly homologous sequences
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
EP3511426B1 (en) 2012-02-01 2022-08-17 Gen-Probe Incorporated Asymmetric hairpin target capture oligomers
WO2013153911A1 (en) * 2012-04-12 2013-10-17 国立大学法人東京大学 Nucleic acid quantification method, detection probe, detection probe set, and nucleic acid detection method
US9535033B2 (en) 2012-08-17 2017-01-03 Quantum Biosystems Inc. Sample analysis method
JP6282036B2 (en) 2012-12-27 2018-02-21 クオンタムバイオシステムズ株式会社 Method and control apparatus for controlling movement speed of substance
GB201306445D0 (en) 2013-04-09 2013-05-22 Base4 Innovation Ltd Single nucleotide detection method
KR102160389B1 (en) 2013-08-05 2020-09-28 트위스트 바이오사이언스 코포레이션 De novo synthesized gene libraries
WO2015042200A1 (en) 2013-09-18 2015-03-26 Osaka University Biomolecule sequencing devices, systems and methods
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
JP2015077652A (en) 2013-10-16 2015-04-23 クオンタムバイオシステムズ株式会社 Nano-gap electrode and method for manufacturing same
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
US20150259743A1 (en) 2013-12-31 2015-09-17 Roche Nimblegen, Inc. Methods of assessing epigenetic regulation of genome function via dna methylation status and systems and kits therefor
EP3090063B1 (en) 2013-12-31 2019-11-06 Bio-Rad Laboratories, Inc. Method for detection of latent retrovirus
US10438811B1 (en) 2014-04-15 2019-10-08 Quantum Biosystems Inc. Methods for forming nano-gap electrodes for use in nanosensors
EP3172321B2 (en) * 2014-07-21 2023-01-04 Illumina, Inc. Polynucleotide enrichment using crispr-cas systems
US9981239B2 (en) 2015-04-21 2018-05-29 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
EP3350314A4 (en) 2015-09-18 2019-02-06 Twist Bioscience Corporation Oligonucleic acid variant libraries and synthesis thereof
KR20180058772A (en) * 2015-09-22 2018-06-01 트위스트 바이오사이언스 코포레이션 Flexible substrate for nucleic acid synthesis
CN115920796A (en) 2015-12-01 2023-04-07 特韦斯特生物科学公司 Functionalized surfaces and preparation thereof
CN109071590B (en) * 2016-03-01 2023-08-08 方馨基因组学公司 System and method for data driven design, synthesis and application of molecular probes
US10870872B2 (en) * 2016-04-04 2020-12-22 President And Fellows Of Harvard College Enzymatic nucleic acid synthesis
KR20190075010A (en) 2016-04-27 2019-06-28 퀀텀 바이오시스템즈 가부시키가이샤 System and method for measurement and sequencing of biomolecules
CA3034769A1 (en) 2016-08-22 2018-03-01 Twist Bioscience Corporation De novo synthesized nucleic acid libraries
US10417457B2 (en) 2016-09-21 2019-09-17 Twist Bioscience Corporation Nucleic acid based data storage
GB2573069A (en) 2016-12-16 2019-10-23 Twist Bioscience Corp Variant libraries of the immunological synapse and synthesis thereof
CA3054303A1 (en) 2017-02-22 2018-08-30 Twist Bioscience Corporation Nucleic acid based data storage
US10894959B2 (en) 2017-03-15 2021-01-19 Twist Bioscience Corporation Variant libraries of the immunological synapse and synthesis thereof
US11920192B2 (en) 2017-05-15 2024-03-05 Lightcast Discovery Ltd Single nucleotide detection method and associated probes
WO2018231864A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
AU2018284227B2 (en) * 2017-06-12 2024-05-02 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
CN111566125A (en) 2017-09-11 2020-08-21 特韦斯特生物科学公司 GPCR binding proteins and synthesis thereof
GB2583590A (en) 2017-10-20 2020-11-04 Twist Bioscience Corp Heated nanowells for polynucleotide synthesis
AU2019205269A1 (en) 2018-01-04 2020-07-30 Twist Bioscience Corporation DNA-based digital information storage
CN112639130B (en) 2018-05-18 2024-08-09 特韦斯特生物科学公司 Polynucleotides, reagents and methods for nucleic acid hybridization
JP7479367B2 (en) 2018-11-29 2024-05-08 ヴェンタナ メディカル システムズ, インク. Individualized ctDNA disease monitoring by representative DNA sequencing
CN109613236B (en) * 2018-12-12 2022-04-15 安邦(厦门)生物科技有限公司 Nucleic acid hybridization capture immunofluorescence detection method, immunofluorescence chromatography test strip and kit
EP3899951A1 (en) 2018-12-23 2021-10-27 F. Hoffmann-La Roche AG Tumor classification based on predicted tumor mutational burden
JP2022521209A (en) * 2019-02-21 2022-04-06 エフ.ホフマン-ラ ロシュ アーゲー Improved Nucleic Acid Target Concentration and Related Methods
WO2020176678A1 (en) 2019-02-26 2020-09-03 Twist Bioscience Corporation Variant nucleic acid libraries for glp1 receptor
JP2022522668A (en) 2019-02-26 2022-04-20 ツイスト バイオサイエンス コーポレーション Mutant nucleic acid library for antibody optimization
CA3144644A1 (en) 2019-06-21 2020-12-24 Twist Bioscience Corporation Barcode-based nucleic acid sequence assembly
AU2020356471A1 (en) 2019-09-23 2022-04-21 Twist Bioscience Corporation Variant nucleic acid libraries for CRTH2

Citations (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2659208A (en) 1947-10-21 1953-11-17 Frankignoul Pieux Armes Drainage pile
US3259408A (en) 1961-05-03 1966-07-05 Trw Inc Ball joint
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5700672A (en) 1992-07-23 1997-12-23 Stratagene Purified thermostable pyrococcus furiousus DNA ligase
US5843669A (en) 1996-01-24 1998-12-01 Third Wave Technologies, Inc. Cleavage of nucleic acid acid using thermostable methoanococcus jannaschii FEN-1 endonucleases
US5874283A (en) 1995-05-30 1999-02-23 John Joseph Harrington Mammalian flap-specific endonuclease
US5888780A (en) 1992-12-07 1999-03-30 Third Wave Technologies, Inc. Rapid detection and identification of nucleic acid variants
US6013440A (en) 1996-03-11 2000-01-11 Affymetrix, Inc. Nucleic acid affinity columns
US6090606A (en) 1996-01-24 2000-07-18 Third Wave Technologies, Inc. Cleavage agents
US6251649B1 (en) 1997-09-04 2001-06-26 Director - General Of Agency Of Industrial Science And Technology Thermostable flap endonuclease derived from a hyperthermophile bacterium belonging to the genus pyrococcus
US6255081B1 (en) 1998-09-03 2001-07-03 Director - General Of Agency Of Industrial Science And Technology Thermostable flap endonuclease derived from hyperthermophile bacterium belonging to the genus pyrococcus
US6295153B1 (en) 1998-06-04 2001-09-25 Board Of Regents, The University Of Texas System Digital optical chemistry micromirror imager
US6315958B1 (en) 1999-11-10 2001-11-13 Wisconsin Alumni Research Foundation Flow cell for synthesis of arrays of DNA probes and the like
US6375903B1 (en) 1998-02-23 2002-04-23 Wisconsin Alumni Research Foundation Method and apparatus for synthesis of arrays of DNA probes
US6444429B1 (en) 1999-11-10 2002-09-03 Korea Institute Of Science And Technology Gene coding for DNA ligase of hyperthermophilic bacteria Aquifex pyrophilus and protein expressed therefrom
US6562611B1 (en) 1996-11-29 2003-05-13 Third Wave Technologies, Ins. FEN-1 endonucleases, mixtures and cleavage methods
US6576453B2 (en) 1996-07-19 2003-06-10 Cornell Research Foundation, Inc. Thermostable DNA ligase mutants
US20030143550A1 (en) 2002-01-31 2003-07-31 Roland Green Correction for illumination non-uniformity during the synthesis of arrays of oligomers
US20040110211A1 (en) 2002-09-27 2004-06-10 Mccormick Mark Microarray with hydrophobic barriers
US20040110212A1 (en) 2002-09-30 2004-06-10 Mccormick Mark Microarrays with visual alignment marks
US20040126757A1 (en) 2002-01-31 2004-07-01 Francesco Cerrina Method and apparatus for synthesis of arrays of DNA probes
WO2005010199A2 (en) * 2003-07-16 2005-02-03 Geneohm Sciences, Inc. Invasive cleavage reaction with electrochemical readout
US6949370B1 (en) 1998-10-30 2005-09-27 Cornell Research Foundation, Inc. High fidelity thermostable ligase and uses thereof
US6979725B2 (en) 1998-12-15 2005-12-27 Pioneer Hi-Bred International, Inc. Rad2/FEN-1 orthologues and uses thereof
US20060040294A1 (en) 1996-01-24 2006-02-23 Prudent James R Cleavage of nucleic acids
US7083975B2 (en) 2002-02-01 2006-08-01 Roland Green Microarray synthesis instrument and method
US20060183207A1 (en) 1996-01-24 2006-08-17 Third Wave Technologies, Inc. FEN endonucleases
US7122364B1 (en) 1998-03-24 2006-10-17 Third Wave Technologies, Inc. FEN endonucleases
US7157229B2 (en) 2002-01-31 2007-01-02 Nimblegen Systems, Inc. Prepatterned substrate for optical synthesis of DNA probes
US20070037190A1 (en) 2005-08-10 2007-02-15 Hirokazu Nishida DNA ligase mutants
WO2007035439A1 (en) 2005-09-15 2007-03-29 New England Biolabs, Inc. Discovery, cloning and purification of thermococcus sp. (strain 9°n-7) dna ligase
US20070105138A1 (en) 1999-10-29 2007-05-10 Sorge Joseph A Method for detection of a target nucleic acid with a FEN nuclease
WO2008045251A2 (en) * 2006-10-04 2008-04-17 Third Wave Technologies, Inc. Snap-back primers and detectable hairpin structures

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194149B1 (en) * 1998-03-03 2001-02-27 Third Wave Technologies, Inc. Target-dependent reactions using structure-bridging oligonucleotides
US6815167B2 (en) * 2002-04-25 2004-11-09 Geneohm Sciences Amplification of DNA to produce single-stranded product of defined sequence and length
US7851150B2 (en) * 2002-12-18 2010-12-14 Third Wave Technologies, Inc. Detection of small nucleic acids
US9297036B2 (en) * 2005-07-01 2016-03-29 Agilent Technologies, Inc Nucleic acid probes for analysis of small RNAs and other polynucleotides

Patent Citations (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2659208A (en) 1947-10-21 1953-11-17 Frankignoul Pieux Armes Drainage pile
US3259408A (en) 1961-05-03 1966-07-05 Trw Inc Ball joint
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5700672A (en) 1992-07-23 1997-12-23 Stratagene Purified thermostable pyrococcus furiousus DNA ligase
US6280998B1 (en) 1992-07-23 2001-08-28 Stratagene Purified thermostable pyrococcus furiosus DNA ligase
US5888780A (en) 1992-12-07 1999-03-30 Third Wave Technologies, Inc. Rapid detection and identification of nucleic acid variants
US5874283A (en) 1995-05-30 1999-02-23 John Joseph Harrington Mammalian flap-specific endonuclease
US20060292580A1 (en) 1996-01-24 2006-12-28 Prudent James R Cleavage of nucleic acids
US20070292856A1 (en) 1996-01-24 2007-12-20 Third Wave Technologies, Inc. Nucleic acid cleavage assays
US6090606A (en) 1996-01-24 2000-07-18 Third Wave Technologies, Inc. Cleavage agents
US20070003942A1 (en) 1996-01-24 2007-01-04 Prudent James R Invasive cleavage of nucleic acids
US20060040294A1 (en) 1996-01-24 2006-02-23 Prudent James R Cleavage of nucleic acids
US5846717A (en) * 1996-01-24 1998-12-08 Third Wave Technologies, Inc. Detection of nucleic acid sequences by invader-directed cleavage
US20060154269A1 (en) 1996-01-24 2006-07-13 Prudent James R Cleavage of nucleic acids
US5843669A (en) 1996-01-24 1998-12-01 Third Wave Technologies, Inc. Cleavage of nucleic acid acid using thermostable methoanococcus jannaschii FEN-1 endonucleases
US20060177835A1 (en) 1996-01-24 2006-08-10 Prudent James R Cleavage of nucleic acids
US20060183207A1 (en) 1996-01-24 2006-08-17 Third Wave Technologies, Inc. FEN endonucleases
US6013440A (en) 1996-03-11 2000-01-11 Affymetrix, Inc. Nucleic acid affinity columns
US6576453B2 (en) 1996-07-19 2003-06-10 Cornell Research Foundation, Inc. Thermostable DNA ligase mutants
US6562611B1 (en) 1996-11-29 2003-05-13 Third Wave Technologies, Ins. FEN-1 endonucleases, mixtures and cleavage methods
US6251649B1 (en) 1997-09-04 2001-06-26 Director - General Of Agency Of Industrial Science And Technology Thermostable flap endonuclease derived from a hyperthermophile bacterium belonging to the genus pyrococcus
US6375903B1 (en) 1998-02-23 2002-04-23 Wisconsin Alumni Research Foundation Method and apparatus for synthesis of arrays of DNA probes
US7122364B1 (en) 1998-03-24 2006-10-17 Third Wave Technologies, Inc. FEN endonucleases
US20030003032A1 (en) 1998-06-04 2003-01-02 Garner Harold R. Digital optical chemistry micromirror imager
US20070140906A1 (en) 1998-06-04 2007-06-21 Garner Harold R Digital optical chemistry micromirror imager
US20020041420A1 (en) 1998-06-04 2002-04-11 Garner Harold R. Digital optical chemistry micromirror imager
US6295153B1 (en) 1998-06-04 2001-09-25 Board Of Regents, The University Of Texas System Digital optical chemistry micromirror imager
US6255081B1 (en) 1998-09-03 2001-07-03 Director - General Of Agency Of Industrial Science And Technology Thermostable flap endonuclease derived from hyperthermophile bacterium belonging to the genus pyrococcus
US20050266487A1 (en) 1998-10-30 2005-12-01 Francis Barany High fidelity thermostable ligase and uses thereof
US6949370B1 (en) 1998-10-30 2005-09-27 Cornell Research Foundation, Inc. High fidelity thermostable ligase and uses thereof
US6979725B2 (en) 1998-12-15 2005-12-27 Pioneer Hi-Bred International, Inc. Rad2/FEN-1 orthologues and uses thereof
US20070105138A1 (en) 1999-10-29 2007-05-10 Sorge Joseph A Method for detection of a target nucleic acid with a FEN nuclease
US20070292864A1 (en) 1999-10-29 2007-12-20 Stratagene California Compositions and methods for detection of a target nucleic acid sequence
US20070292934A1 (en) 1999-10-29 2007-12-20 Stratagene California Compositions and methods for detection of a target nucleic acid sequence
US20070231815A1 (en) 1999-10-29 2007-10-04 Stratagene California Compositions and kits for detection of a target nucleic acid
US6315958B1 (en) 1999-11-10 2001-11-13 Wisconsin Alumni Research Foundation Flow cell for synthesis of arrays of DNA probes and the like
US6444429B1 (en) 1999-11-10 2002-09-03 Korea Institute Of Science And Technology Gene coding for DNA ligase of hyperthermophilic bacteria Aquifex pyrophilus and protein expressed therefrom
US6444175B1 (en) 1999-11-10 2002-09-03 Wisconsin Alumni Research Foundation Flow cell for synthesis of arrays of DNA probes and the like
US20040126757A1 (en) 2002-01-31 2004-07-01 Francesco Cerrina Method and apparatus for synthesis of arrays of DNA probes
US20030143550A1 (en) 2002-01-31 2003-07-31 Roland Green Correction for illumination non-uniformity during the synthesis of arrays of oligomers
US7157229B2 (en) 2002-01-31 2007-01-02 Nimblegen Systems, Inc. Prepatterned substrate for optical synthesis of DNA probes
US20070037274A1 (en) 2002-02-01 2007-02-15 Roland Green Microarray synthesis instrument and method
US7083975B2 (en) 2002-02-01 2006-08-01 Roland Green Microarray synthesis instrument and method
US20040110211A1 (en) 2002-09-27 2004-06-10 Mccormick Mark Microarray with hydrophobic barriers
US20040110212A1 (en) 2002-09-30 2004-06-10 Mccormick Mark Microarrays with visual alignment marks
WO2005010199A2 (en) * 2003-07-16 2005-02-03 Geneohm Sciences, Inc. Invasive cleavage reaction with electrochemical readout
US20070037190A1 (en) 2005-08-10 2007-02-15 Hirokazu Nishida DNA ligase mutants
WO2007035439A1 (en) 2005-09-15 2007-03-29 New England Biolabs, Inc. Discovery, cloning and purification of thermococcus sp. (strain 9°n-7) dna ligase
WO2008045251A2 (en) * 2006-10-04 2008-04-17 Third Wave Technologies, Inc. Snap-back primers and detectable hairpin structures

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
ALBERT, T.J. ET AL., NAT. METH., vol. 4, 2007, pages 903 - 5
ALBERT, T.J. ET AL., NUCL ACIDS RES, vol. 31, no. 7, 2003, pages E35
ANTAO, V.P. ET AL., NUCL ACIDS RES, vol. 19, no. 21, 1991, pages 5901 - 5
BOWTELL AND SAMBROOK,: "DNA Microarrays: A Molecular Cloning Manual", 2003, COLD SPRING HARBOR LABORATORY PRESS
BROUDE N E ET AL: "DNA microarrays with stem-loop DNA probes: preparation and applications", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 29, no. 19, 1 January 2001 (2001-01-01), pages E92, XP002993367, ISSN: 0305-1048 *
FORS L ET AL: "LARGE-SCALE SNP SCORING FROM UNAMPLIFIED GENOMIC DNA", PHARMACOGENOMICS, ASHLEY PUBLICATIONS, GB, vol. 1, no. 2, 1 January 2000 (2000-01-01), pages 219 - 229, XP001064659, ISSN: 1462-2416 *
HAN EUGENE S ET AL: "RecJ exonuclease: substrates, products and interaction with SSB", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, GB, vol. 34, no. 4, 1 January 2006 (2006-01-01), pages 1084 - 1091, XP009114522, ISSN: 1362-4962 *
HAN, E.S. ET AL., NUCL ACIDS RES, vol. 34, no. 4, 2006, pages 1084 - 1091
HARRINGTON, J.J.; LIEBER, M.R., EMBO J, vol. 13, no. 5, 1994, pages 1235 - 46
HARRINGTON, J.J.; LIEBER, M.R., J BIOL CHEM, vol. 270, no. 9, 1995, pages 4503 - 8
LOVETT, S.T.; KOLODNER, R.D., PROC NATL ACAD SCI, vol. 86, 1989, pages 2627 - 2631
OKOU, D.T. ET AL., NAT. METH., vol. 4, no. 11, 2007, pages 907 - 9
RONAGHI, M. ET AL., SCIENCE, vol. 281, 1998, pages 363 - 65
SAMBROOK ET AL.,: "Molecular Cloning, A Laboratory Manual", COLD SPRING HARBOR PRESS
VARANI, G., ANN REV BIOPHYS BIOMOL STRUCT, vol. 24, 1995, pages 379 - 404
WETMUR, J.G., CRIT REV BIO MOL BIOL, vol. 26, no. 3/4, 1991, pages 227 - 59
WETMUR, J.G.; DAVIDSON, M., J MOL BIOL, vol. 31, 1968, pages 349 - 70
WILKINS STEVENS P ET AL: "Analysis of single nucleotide polymorphisms with solid phase invasive cleavage reactions", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 29, no. 16, 15 August 2001 (2001-08-15), pages E77, XP002317017, ISSN: 0305-1048 *
YAMAGATA, A. ET AL., NUCL ACIDS RES, vol. 29, no. 22, 2001, pages 4617 - 4624

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10557851B2 (en) 2012-03-27 2020-02-11 Ventana Medical Systems, Inc. Signaling conjugates and methods of use
US11906523B2 (en) 2012-03-27 2024-02-20 Ventana Medical Systems, Inc. Signaling conjugates and methods of use
EP3759243B1 (en) * 2018-02-28 2023-09-27 Synpromics Ltd. Methods and compositions for enriching nucleic acids
EP4299740A3 (en) * 2018-02-28 2024-05-15 Asklepios Biopharmaceutical, Inc. Methods and compositions for enriching nucleic acids

Also Published As

Publication number Publication date
US20090246788A1 (en) 2009-10-01
CN102046811A (en) 2011-05-04
EP2262909A1 (en) 2010-12-22
JP2011516050A (en) 2011-05-26
CA2725405A1 (en) 2009-10-08

Similar Documents

Publication Publication Date Title
US20090246788A1 (en) Methods and Assays for Capture of Nucleic Acids
US8664164B2 (en) Probes for specific analysis of nucleic acids
US7108976B2 (en) Complexity management of genomic DNA by locus specific amplification
CA2699835C (en) Methods and systems for solution based sequence enrichment and analysis of genomic regions
EP1645640B1 (en) Method for detecting chromosomal translocations
US20100222232A1 (en) Enrichment and sequence analysis of genomic regions
CA2559541A1 (en) Methods and means for nucleic acid sequencing
JP2004524012A (en) Isothermal amplification of nucleic acids on solid supports
EP1090138A1 (en) Nucleotide detection method
WO2004099431A2 (en) Nucleic acid sequence detection using multiplexed oligonucleotide pcr
US7189512B2 (en) Methods for variation detection
US6653079B2 (en) Methods for detection of differences in nucleic acids
WO2009109753A2 (en) Multiplex selection and sequencing
US20080102450A1 (en) Detecting DNA methylation patterns in genomic DNA using bisulfite-catalyzed transamination of CpGS
US20230220474A1 (en) Sequence conversion reaction
US20100285970A1 (en) Methods of sequencing nucleic acids
Park et al. DNA Microarray‐Based Technologies to Genotype Single Nucleotide Polymorphisms
WO2023107713A2 (en) Sequence conversion reaction
WO2003070977A2 (en) Method for detecting single nucleotide polymorphisms
US20040235004A1 (en) Methods for detection of differences in nucleic acids
CA2402483A1 (en) Methods for detection of differences in nucleic acids
AU2001245634A1 (en) Methods for detection of differences in nucleic acids

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980119976.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09727453

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2009727453

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2725405

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2011502277

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE